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Abstract of the Dissertation 
Exploring Infant Leukemia through Exome Sequencing and an In Vitro Model of Hematopoietic 
Development 
by 
Mark Cannon Valentine 
Doctor of Philosophy in Biology and Biomedical Sciences 
Human and Statistical Genetics 
Washington University in St. Louis, 2019 
Todd Druley, Chair 
Cancer is a heterogeneous disease with myriad causes and outcomes.  Many of the cancers that 
occur in adult populations have become increasingly well characterized with the advent of 
affordable high-throughput sequencing. These studies have revealed that cancer is largely a 
disease of somatic mutation in the adult population.  In strong contrast to this, childhood cancers 
have an exceedingly low rate of somatic mutation. At the extreme end of this spectrum is Infant 
Leukemia (IL). Sequencing of IL has revealed that these tumors generally have one or fewer 
somatic SNP. In the absence of a somatic explanation for IL, many other possible explanations 
have been put forth. To date, however, none of these has been able to fully explain the incidence 
of this disease. In this context, we hypothesized that inherited germline variation, rather than 
somatically acquired mutations, played a role in the development of IL. We showed that IL 
patients have an excess of rare, non-synonymous, inherited variation in known-leukemia 
associated genes.  We further showed that there are several genes that harbor far more putatively 
damaging variation in IL patients than either control exomes, or population databases. These 
highly variant genes are intolerant of loss-of-function changes, and most perform one of three 
xii 
 
critical cellular functions. Together these data suggest that IL is indeed a result of predisposing 
genetic variation.  
Obtaining a clearer understanding of IL has been hindered by the lack of an appropriate model.  
The fact that this disease arises in utero makes it difficult to study in vivo, and no animal models 
have been able to recapitulate the rapid onset of disease.  In recent years, several groups have 
developed in vitro models of human hematopoiesis.  While these are not yet able to fully capture 
all aspects of hematopoietic development, they do provide a system in which we can explore the 
effects of the genetic variation observed in IL patients in a controlled and developmentally 
relevant setting. Importantly, we are able to effectively separate the primitive and definitive 
hematopoietic programs and explore each independently, a necessary feature for any IL model. 
In this work, we present the first steps in the development of a model of IL that is consistent with 
our sequencing findings. While we do not achieve leukemic transformation, we do show that 
cells deficient in MLL3, a gene that was frequently variant in our IL cohorts, have a marked 
impairment in both primitive and definitive hematopoiesis. We find that this is evident both 
based on surface markers and colony forming ability. In addition to these functional 
characteristics, we show that the transcriptional and epigenetic profiles of the MLL3-knockout 
cells are greatly perturbed, consistent with the role of MLL3 as a transcriptional enhancer and 
epigenetic regulator. These results provide insight into the etiology of IL as a disease of aberrant 
development, and provide a basis for the establishment of an in vitro model of IL. 
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1. Introduction 
1.1 Infant Leukemia 
1.1.1 Cancer 
Cancer is a disease that has been affecting humanity for thousands of years1. Descriptions of the 
disease and its causes and treatments are present in ancient Egyptian, Sumerian, Hebrew, Indian, 
Persian, Chinese and Greek texts1,2. The struggle to understand and better treat this mystifying 
and frequently fatal disease may have begun with these early physicians, but these efforts have 
grown throughout the years and are continued in earnest today3–7. Many breakthroughs have 
been made, and our understanding of the features, risk factors and driving forces behind cancer is 
more complete than ever.  One of the most important discoveries has been the recognition that 
various cancers, while linked through some similarities, are actually a diverse group of 
diseases2,8–10. The nature and behavior of a given cancer will be influenced by the tissue and cell 
of origin, the specific genetic and epigenetic lesions present in the tumor, the age at diagnosis 
and potentially many other factors2. Indeed, cancers arising in different tissues, but containing 
the same genetic lesion may respond more similarly to certain treatments than cancers from the 
same tissue, but with different underlying genetics11–14.  Similarly, a cancer from a given tissue 
diagnosed in childhood can differ in genetics, treatment susceptibility, and prognosis than one 
from the same tissue but diagnosed in adulthood15,16.   
This heterogeneity in cancer is further evidenced by the large range in the mutational burden 
present in different cancer types17,18.  As expected, cancers with known mutagenic exposures (eg. 
melanoma, lung adenocarcinoma in smokers) have a much higher rate of mutation than those 
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without.  At the opposite extreme this mutational spectrum are the pediatric cancers, which, as a 
group, tend to have fewer somatic mutations than their adult counterparts17,19,20.   
While there is clearly a great deal of heterogeneity in cancer, perhaps the strongest link between 
cancers is that each is a disease of the genome, having a number of genetic changes that leads to 
the development, growth and spread of cancer17,21. Initially, it seems that this link no longer 
holds in the context of pediatric cancers which, especially in the extreme example of infant 
leukemia, have far fewer somatic mutations than adult tumors22. However, cancer is ever the 
diverse disease, so it holds that the types of genetic damage that underlie its development would 
be similarly diverse. Indeed, there are numerous known inherited genetic variants that predispose 
individuals to cancer23,24. While these cancer predisposition genes lessen the requirement for 
subsequent somatic mutation to develop cancer, they rarely result in cancer in childhood, even 
less so in infancy. Still, they do provide evidence that inherited germline variants play a role in 
the development of cancer. It is possible that combinations of inherited variants would lead to 
more extreme phenotypes. The requirement for the co-occurrence of multiple rare events would 
potentially explain the rarity of these diseases as well as their extreme early onset. To explore 
this possibility we turned to the extreme example of infant leukemia. 
1.1.2 Features and Outcomes of Infant Leukemia 
Infant Leukemia (IL) is defined as any leukemia diagnosed in the first year of life.  There are 5 
new IL cases diagnosed per 100,000 individuals each year25. In contrast to leukemia later in 
childhood, IL has a dismal 5-year event free survival rate of less than 50%26,27. This failure 
comes despite the achievement of complete remission in more than 90% of patients26. Early 
relapse is common in IL and has not been prevented by either intensified therapy or stem cell 
transfer26–28.  There are several negative prognostic factors for IL patients. Younger age at 
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diagnosis, hyperleukocytosis, poor initial treatment response, immature cell types and the 
presence of chromosomal translocations involving KMT2A all negatively affect outcomes in 
these infants29–31. Patients who do survive have deficits in organ function, growth and learning 
throughout later life, presumably due to the intensity of treatment regimens early in life32–34. 
1.1.3 Risk Factors for Infant Leukemia 
IL has one of the lowest rates of somatic mutation of any cancer studied to date22.  This paucity 
of somatic mutation prompts the question of what is causing IL.  Several suggestions that will be 
outlined below have been made to date, but none adequately explain the incidence of IL.  One of 
the most common features present in IL are chromosomal rearrangements involving KMT2A 
(also known as MLL) and one of more than 70 fusion partners30.  IL cases with KMT2A 
rearrangements (KMT2A-R+) are particularly aggressive.  However, KMT2A rearrangements 
are not necessary for the development of IL, as 20% of IL cases are negative (KMT2A-R-) for 
this event27,29.  Also, despite some arguments that MLL-rearrangements alone might drive IL35 , 
other studies show that this event alone is insufficient to explain IL36–38. 
Absent somatic events to explain IL, many other possible causes have been explored.  A number 
of environmental factors have been interrogated. In summary, there was no appreciable increase 
of pediatric cancer incidence as a result of background radiation, non-ionizing radiation, electric 
fields, childhood infections, vaccinations, breast feeding or daycare attendance39. Conversely, 
maternal consumption of naturally occurring topoisomerase II inhibitors did increase the risk of 
KMT2A-R+ AML in their infants40. Similarly, children with KMT2A-R+ leukemia were more 
likely to have decreased function in NAD(P)H:quinone oxidoreductase, an association that was 
even more pronounced in infants41. Another study presented evidence that specific variants in the 
methylenetetrahydrofolate reductase gene conferred protection against the development of 
4 
 
KMT2A-R+ leukemia42. Together these studies show that there are environmental risk factors 
for IL, some of which interact with inherited variants. Even in aggregate, these findings do not 
fully explain the occurrence of IL, but they do support the notion that inherited variants can play 
an important role in the development of IL. 
1.2 Hematopoietic Development 
We hypothesize that inherited variation is responsible, at least in part, for the development of IL. 
This variation is present from the time of conception. IL also develops in utero43. This timing 
suggests that IL might be a result of developmental processes gone awry. In order to explore this 
idea more fully, we must first understand the normal sequence of events, and the relevant 
pathways, cell types and processes that occur during normal hematopoietic development. 
Further, if we wish to model these processes, we will need a tractable system with understood 
readouts so that we can detect deviations from normal.  To achieve these goals, we turn to a 
human pluripotent stem cell (hPSC) – based directed differentiation system, based on insights 
into development derived from various model organisms.  
1.2.1 Hematopoiesis in the Embryo 
Hematopoiesis, the process by which the body forms new blood cells, has been an active area of 
research for many decades. In the adult human, hematopoiesis occurs in the bone marrow and 
begins with hematopoietic stem cells, which have the capacity to both self-renew and 
differentiate into all blood lineages44. This adult program is established in utero, but is preceded 
by two waves of earlier hematopoietic programs45. The earliest of these, called the primitive 
program, begins during the third week of gestation46,47. Primitive hematopoiesis occurs, not in 
the embryo proper, but in blood islands located in the yolk sac48.  Primitive hematopoietic cells 
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arise concurrently with endothelial cells and are both derived from a common mesodermal 
precursor, the hemangioblast49–51. The primitive program does not give rise to all blood lineages, 
but is restricted to macrophages, megakaryocytes47 and primitive erythroblasts, which retain their 
nuclei and express embryonic globins52,53. There are no primitive HSCs, but some of the cells 
generated by this program might seed developing embryonic tissues and persist there throughout 
life54. 
A second extra-embryonic wave of hematopoiesis occurs soon after the primitive program. This 
program generates a population of erythro-myeloid progenitors (EMPs) which are distinct from 
both the earlier primitive program and the later definitive program54,55.  The EMPs give rise to an 
expanded set of lineages relative to primitive progenitors, including definitive erythroid, 
megakaryocyte, macrophage, neutrophil and mast cell progenitors, but do not have lymphoid 
potential55. 
The definitive hematopoietic program is also established in utero, but arises after the other 
programs have begun45. Like the other programs, definitive hematopoietic progenitors are 
derived from a subset of endothelial cells that have hematopoietic potential, dubbed hemogenic 
endothelium56,57. The best-studied hemogenic endothelium is the aorta-gonad-mesonephros 
region, but it is also present in the vitelline and umbilical arteries and the head54,58,59. These 
hemogenic endothelial cells undergo an endothelial-to-hematopoietic transition (EHT) to enter 
the newly forming circulation60,61. These cells represent the first definitive HSCs, and will go on 
to seed the fetal liver and eventually the bone marrow45. The definitive program gives rise to the 
entire spectrum of hematopoietic lineages: erythroid, myeloid and lymphoid62.  
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Decades of research have elucidated many of the genes that are responsible for the various 
hematopoietic programs. The genes that are required for primitive hematopoiesis frequently 
encode transcription factors important for many developmental processes. These include LMO2, 
TAL1 and GATA262–69. Similarly, the definitive hematopoietic program depends on the 
transcription factors encoded by RUNX1, MYB, CEBPZ, IKZF1, LHX2, REL and SPI1 70–80. 
There are also several genes and gene families that play a role in regulating hematopoiesis that 
enforce different programs in different species, or act in both the primitive and definitive 
program.  These include the CDX genes, and several HOX genes81–83. The induction of these 
transcription factors depends on input from several signaling pathways including Nodal-activin, 
bone morphogenetic protein (BMP), WNT-β-Catenin, Fibroblast Growth Factor (FGF), and 
Notch84–88. Clearly, these genes do not form an exhaustive list; new regulators of the complex 
process of hematopoietic development will continue to be discovered.  Still, the knowledge of 
the various roles that these genes play is critical to both understanding developmental 
hematopoiesis, and attempting to model this process in vitro. 
1.2.2 In vitro 
The ability to generate HSCs reliably and efficiently in vitro would be incredibly valuable as a 
therapeutic tool to treat various hematopoietic malignancies and disorders, as a model of various 
diseases, and as a scientific tool to explore hematopoietic development54,89. This ability remains 
elusive, but, given its immense promise, many researchers are actively developing and refining 
methods to this end. Two major strategies for in vitro hematopoietic differentiation from hPSCs 
exist. In the first, hPSCs are co-cultured with stromal cells in the presence of serum and 
cytokines90. While this method does generate a variety of hematopoietic cells, it does so with 
low-efficiency, and is dominated largely by primitive or EMP-derived lineages91. The second 
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method uses a directed differentiation approach, providing the signals that are present during 
normal development92. This method benefits from its ability modulate signaling pathways to 
derive purely primitive or purely definitive cell populations from a given culture93,94. Using this 
method, the authors were able to generate and identify a hemogenic endothelial population that 
gave rise to all of the hematopoietic cells in their culture56. Unfortunately, no in vitro 
differentiation protocol has been able to generate and maintain HSCs. However, the fact that the 
directed development approaches are able to undergo definitive hematopoiesis, as evidenced by 
the presence of T-lymphocytes93, and generate cells from other hematopoietic lineages, strongly 
suggests that some of the cells in these cultures pass through an HSC-like stage. The features of 
the latter system make it the best option for modeling IL through the introduction of specific 
lesions observed in patients. 
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2. Early Sequencing 
2.1 Introduction 
In an initial effort to explore the role of germline variation in the development of IL, we obtained 
germline DNA samples from a cohort of IL patients and their mothers.  Much work had been 
done focusing on KMT2A-R+ leukemia, and there was speculation that this single somatic event 
was a sufficiently powerful driver that it might greatly decrease the necessity for other genetic 
damage35. Thus, to maximize the chance of finding germline variants that contribute to the 
development of IL, we restricted this initial study to KMT2A-R- leukemia. 
2.2 Methods 
2.2.1 Patient information and DNA samples 
DNA samples and demographic and clinical information were collected from 23 pairs of 
deidentified Caucasian mothers and their infants with KMT2A-R- acute leukemia who were 
enrolled on the COG-AE24: ‘Epidemiology of Infant Leukemia’ protocol. Briefly, infants (<12 
months) with a confirmed diagnosis of ALL or AML during the period 1996–2006 at North 
American COG institutions were eligible for the parent AE24 study; cases with Down syndrome 
were excluded. None of the infants included in this study were reported to have birthmarks, birth 
defects, known chromosomal abnormalities or family histories of pediatric cancers. In addition to 
providing buccal cell samples for themselves (via mouthwash) and their infants in first remission 
(via cytobrushing) using Puregene Buccal Cell Kit (Gentra Systems, Minneapolis, MN USA), as 
well as consent for genetic research using the samples, mothers also released their child’s 
diagnostic information, including results of Southern blot, reverse transcription-PCR, fluorescent 
in situ hybridization or other cytogenetics testing, to permit central review. Three independent 
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reviewers evaluated submitted materials to confirm diagnoses and classify the leukemia as 
KMT2A-R+, KMT2A-R- or indeterminate. Institutional Review Boards at the University of 
Minnesota Coordinating Center (#0309M52104) and participating COG institutions approved the 
parent AE24 study. Control pediatric exomes were obtained from Caucasian infants and their 
parents without cancer collected as part of an exome sequencing initiative conducted by the 
Newborn Medicine Division at St Louis Children’s Hospital (courtesy of F Sessions Cole, MD). 
Exome sequencing was approved by Washington University Human Research Protection Office 
ID# 201105062. 
2.2.2 Exome sequencing and data analysis 
For all samples, 15–25 ng of germline DNA was whole-genome amplified using the Sigma 
GenomePlex kit according to the manufacturer’s protocol (Sigma, St Louis, MO, USA). From 
each amplified product, 1 μg was used for sequencing library preparation according to the 
Illumina TruSeq DNA Sample Prep v2 kit followed by hybridization capture of each exome 
according to the Illumina TruSeq Exome Enrichment Kit (Illumina, San Diego, CA, USA). 
Libraries were sequenced three/lane on the Illumina HiSeq 2000 platform generating 101 bp 
paired-end reads by the Genome Technology Access Center at Washington University. 
For all exome data from probands, mothers and controls, we used a published bioinformatic 
pipeline95 with sensitivity of 96.9% and specificity of 99.8% with exome analysis for raw data 
alignment and variant calling. Raw sequence data in fastq format were aligned to the NCBI 
human genome build 37 (hg19) using a purchased, multi-threading version of Novoalign version 
2.05 (www.novocraft.com) and published thresholds. An alignment threshold of 200 was used (-t 
200), with adapter stripping (5′-a AGATCGGAAGAGCG-3′) and quality calibration enabled (-
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k). Reads with multiple alignments were discarded (-r none, -e 1) and output was in SAM format 
(-o SAM). Variant calling from the aligned output for the individual exomes was then performed 
using SAMtools96. The aligned data were converted to BAM format to allow the removal of 
duplicate reads using Picard ‘MarkDuplicates’. Variants were then called with the SAMtools 
version 0.1.18 mpileup command, using options -AB –ugf and bcftools ‘view’ with settings -
bvcg. Finally, variants were filtered with vcfutils ‘varFilter’ using default settings except 
retaining all variants with under 99999 reads. This process ultimately yielded a comprehensive 
list of exomic variants for each subject, including single-nucleotide variants and short insertions 
and deletions. ‘Raw’ variant calls from each sample were further filtered by retaining only 
variants with greater than or equal to5-fold coverage/allele (>10-fold/base position), a genotype 
quality score of greater than or equal to 10 and a mapping quality score of greater than or equal 
to60. Although greater than or equal to 5-fold coverage/allele was a bare minimum, it should be 
noted that our average coverage per variant per exome was 21.5-fold/allele (43-fold/base 
position). Each of the individual quality score thresholds will only retain a variant position with 
at least a 95% likelihood of being a true variant. When applied together, the probability of a 
variant miscall is significantly reduced. All remaining variants were used as input for the 
‘variants_reduction.pl’ tool provided with the ANNOVAR software package 
(http://www.openbioinformatics.org/annovar/)97. To enrich for high-confidence variants likely to 
confer a functional consequence, successive filters were applied, keeping only variants which 
were non-synonymous and coding or at splice junctions, and were rare (present at <1% minor 
allele frequency) in either the 1000 Genomes Project (April 2012 release) or in the dbSNP130 
Non-Flagged variants lists. Sequencing results are available at the NCBI Short Read Archive 
under accession number SRP024273. 
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2.2.3 Candidate Gene Selection 
Using version 63 (ALL) or version 64 (AML) of the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/)98, we compiled lists of genes 
relevant in AML and ALL. To do this, we used the Tissue search feature, selecting samples from 
‘hematopoietic and lymphoid’ tissue followed by ‘NS’ for Subtissue type. For AML, we further 
refined our gene list by selecting ‘hematopoietic’ from the Histology menu and, from the 
subHistology menu, ‘Acute myeloid leukaemia’, ‘Acute myeloid leukaemia associated with 
MDS’, ‘Acute myeloid leukaemia myelodysplastic syndrome therapy related NOS’ and ‘Acute 
myeloid leukaemia therapy related’. For ALL, we selected ‘Lymphoid Neoplasm’ from the 
Histology menu followed by ‘Acute lymphoblastic leukaemia’ and ‘Acute lymphoblastic B cell 
leukaemia’ from the subHistology menu. Having filtered by tissue and histology, we selected all 
genes with sequence variation in our cohort, which yielded a list of 126 ALL-associated genes 
and 655 AML-associated genes. Thirty-four genes were shared between candidate gene sets. 
These genes are listed in Table 2.1. 
2.2.4 Hypergeometric and permutation testing 
Hypergeometric (Fisher’s Exact) testing was performed using the ‘phyper’ function in the R 
software statistics package (version 2.15.3; available at http://www.r-project.org). P-values 
(using an α=0.005 to increase stringency) were generated by comparing the aggregate number of 
rare, non-synonymous, predicted deleterious variation in each patient group against either the 
matched mothers, the unaffected control population, the opposite patient group or the opposite 
group of mothers. Unaffected controls consisted of 12 unaffected Caucasian pediatric exomes. 
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Permutation analysis was executed in the R software package using the ‘sample’ function in the 
base package. Using this function, a distribution of the number of rare (not listed in dbSNP 135 
or the 1000 Genomes Project), non-synonymous variants was created by performing 100 000 
iterations of randomly selecting the number of genes identified via filtering (126 ALL-associated 
genes or 655 AML-associated genes). 
2.2.5 Dideoxy sequencing 
Confirmatory dideoxy sequencing was performed at Washington University’s Protein and 
Nucleic Acid Chemistry Laboratory using primers listed in Table 2.2. 
2.3 Results 
Table 2.3 shows the maternal and infant demographics in the ALL and AML subgroups. The 
infants with AML presented somewhat earlier than those with ALL (5.3 months vs 8.3 months), 
but otherwise there were no differences between the subgroups. Maternal age also did not 
associate with phenotype. 
Table 2.4 shows that the average amount of congenital coding variation is higher in affected 
infants than in mothers or unaffected controls. For infants with ALL, our range of 463–3209 
(including insertions and deletions) is consistent with the range of 791–1462 single-nucleotide 
variants per child reported by Chang99. To focus on variants more likely to impart a functional 
effect associated with acute leukemia, we identified 126 ALL-associated genes and 655 AML-
associated genes within the COSMIC database. From these candidate genes, we tabulated the 
number of congenital variants that were rare and non-synonymous. We found an average of 12 
variants per ALL patient in the 126 ALL-associated genes and 163 variants per AML patient in 
the 655 AML-associated genes, both values exceeded the averages of 6 and 132 observed in 
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ALL and AML mothers, respectively, as well as the 2 and 28 observed in controls (Table 2.5). 
Rare, non-synonymous variants in infants with ALL or AML were 2.0 and 1.4 times more likely, 
respectively, to be found in leukemia-associated genes compared with controls (Table 2.5). 
There was no correlation between the number of rare, non-synonymous and putatively 
deleterious variants identified and the size of the gene: R2=0.21 (ALL) and 0.15 (AML). Given 
the unexpectedly large numbers of variants identified in candidate genes, infants were tested for 
an enrichment of variation in candidate genes using a hypergeometric test (Table 2.5). We found 
that, compared with controls, IL patients and mothers demonstrated a statistically significant 
enrichment of variation within either set of candidate genes. These results suggest that IL 
patients are indeed enriched for rare, deleterious variation in leukemia-associated genes. 
Several factors might lead to bias in the variant distribution of our samples.  For example, 
differing transcript sizes or systematic sequencing error. To address these potential biases, we 
performed a randomization test wherein we generated a random set of genes that was the same 
size as the set of variant genes observed in our samples (7808 in ALL and 8422 in AML), and 
recorded the number of COSMIC genes in each random set (Figure 2.1). We repeated this 
procedure 100 000 times and found that the randomly generated sets with the same number of 
COSMIC genes were not observed for either ALL or AML.  This supports the conclusion that 
the observed enrichment was not due to systematic errors and was specific to our patients. 
Alternatively, we also generated 100 000 random lists of only 126 or 655 genes and recorded the 
number of variant genes observed in each iteration. Results (not shown) were qualitatively the 
same as our initial permutation experiment. Results of maternal random permutation testing are 
shown in Figure 2.2. Maternal exomes also demonstrate, to a lesser degree than infants, an 
enrichment of rare, deleterious variation in leukemia-associated genes but none of these mothers 
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had developed leukemia at the time of study enrollment. We also validated our sequencing 
variant calls that were unique to an individual with additional dideoxy sequencing (Table 2.6). 
We did not validate variants observed in matched mothers and infants, as such a result by chance 
would be exceptionally unlikely. 
To prioritize genes that may be most relevant to IL and highlight the combinatorial nature of 
maternal and non-maternal germline variation, we looked for (a) compound heterozygous genes 
and (b) genes that were the most commonly variant across all patients. We surveyed all genes for 
compound heterozygotes, where a gene must show at least two rare, non-synonymous and 
deleterious variants with at least one seen in the matching mother and at least one variant that 
was non-maternal. We found that every AML infant was a compound heterozygote for only two 
genes: KMT2C and ANKRD36. ANKRD36 (ankyrin repeat domain 36) was not a leukemia 
candidate gene and has not been previously associated to leukemia. We focused on KMT2C 
because it was in our AML-candidate gene list and owing to its direct connection to leukemia. 
Interestingly, despite the fact that KMT2C was not on our ALL-candidate gene list, we found 
that 50% of infants with ALL were also compound heterozygotes. Within KMT2C, we identified 
nine stop gain variants (Figure 2.3). Six of these were caused by a known, rare T insertion at 
chr7:151945072 (rs150073007) and three of these were seen in the matching mothers (four of 
nine total). For other candidate genes, 67% of AML patients were also compound heterozygotes 
for RYR1 and FLG, whereas 50% of ALL patients were compound heterozygotes for RBMX. 
We next plotted the top 50 variant candidate genes for infants (Figure 2.4). We found the most 
variant (but not necessarily compound heterozygotes) AML-associated genes in infants with 
AML were TTN, KMT2C and FLG (Figure 2.4, columns 1,3,4; Infants: AML), but from the 
ALL-associated gene list, MDN1, SYNE1 and KMT2B (Figure 2.4, columns 1,2,3; Infants: 
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AML) were frequently variable. For infants with ALL, we found that MDN1 was the most 
variable ALL-associated gene (Figure 2.4, column 1; Infants: ALL), but also noted frequent 
variation in TTN, RBMX and KMT2C from the AML candidate list (Figure 2.4, columns 1,2,3; 
Infants: ALL). Individual variants and their observed frequencies for the top three most 
frequently variant ALL and AML-candidate genes are listed in Tables 2.7 and 2.8. Consistent 
with the hypothesis of a combinatorial inheritance of functionally significant variation in 
leukemia-associated genes, infants generally show greater variability than mothers. We also 
observed that infants with AML tend to have more variants across the top genes than ALL 
infants. 
2.4 Discussion 
Clearly, a critical component of IL etiology remains undiscovered. The search for these 
additional insults has been ongoing for decades and has mainly focused on the acquisition of 
additional somatic mutations within the pre-leukemic clones due either to (a) enhanced 
mechanisms of mutagenesis from the initial genetic defect or (b) environmental exposures to 
toxins that promote DNA mutation. Assuming that the typical cancer requires 2–8 mutation in 
genes regulating cell fate, cell survival and/or genome maintenance17, neither of these 
mechanisms appears sufficient to account for the incidence of IL, and genome-sequencing results 
from KMT2A-R+ infant ALL reported exceptionally few somatic mutations in these three 
classes of genes22. One category of genetic variation that has not been deeply explored in these 
patients is rare germline variants. The aptly named model of ‘clan genomics’ by Lupski and 
colleagues100 posits that combinations of rare and private alleles, in the right genomic context, 
can combine to exert profound, but variable, influence on complex phenotypes. Considering this 
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model, we hypothesized that profiles of rare, coding germline variation may comprise some 
proportion of the expected functional variation typically observed in cancer, but as of yet, not 
observed in IL under a model of somatic mutation. Under this model, each parent possesses a 
partial profile of variation, individually insufficient to significantly increase cancer risk, but 
through random segregation these alleles align in an offspring and result in the right context to 
significantly increase that child’s risk of early leukemogenesis. A recent genome-wide 
association study found support for an additive model of common variants influencing standard-
risk pediatric ALL and proposed that additional low-risk and very rare variants are likely to be 
present and exerting substantial effects on ALL risk101.  The Rare Variant Hypothesis posits that 
a singular complex phenotype may demonstrate a wide variety of functionally significant genetic 
variants in critical genes or metabolic pathways102.  Support for this hypothesis is provided by 
recent studies asserting that genetic variance for complex traits is mostly additive in nature103.  
These congenital profiles of variation may consist of very rare variants of strong effect that may 
be augmented or modulated by additional low-risk variants, which is consistent with reports 
describing how multiple functional variants are required for a normal cell to undergo malignant 
transformation104. 
Although KMT2A-R+ IL has been intensively studied, there are few studies of KMT2A-R− IL 
and none simultaneously characterizing large-scale maternal sequencing. To our knowledge, this 
is the largest sequencing survey of KMT2A-R− IL. In exome sequencing of non-cancer DNA 
from matched mothers and their infants who developed acute leukemia, we find a statistically 
significant excess of rare, non-synonymous and predicted deleterious sequence variants in genes 
already known to be mutated in hematologic malignancies in the COSMIC database. In addition, 
mothers demonstrated enrichment in candidate gene variation over the control population 
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supporting the interpretation that the observed enrichment in infants is a chance occurrence 
resulting from the independent segregation of multiple rare variants inherited from each parent, 
who individually possess a lesser enrichment of variation in the genes in question. Therefore, 
consistent with existing models of carcinogenesis17,103, leukemia can only arise after a discrete 
threshold of deleterious functional variation is surpassed, whether inherited or acquired. Because 
paternal, sibling and patient leukemia DNA were unavailable in the AE24 study, our ability to 
distinguish inherited variation versus de novo mutation, identify potentially more penetrant 
combinations of inherited variants and correlate these patterns with the presence of any somatic 
mutation is limited. However, the patients in our survey were part of an epidemiologic study that 
failed to identify significant in utero exposures accounting for their IL105. A recent review of de 
novo mutation rates in autistic spectrum disorders reports that only one de novo mutation per 
exome is observed in cases that are significantly enriched for de novo mutations106. Thus, 
although we cannot distinguish paternal variation from de novo mutations, elevated rates of de 
novo mutation are insufficient to account for the overall enrichment of variation in candidate 
genes we have identified in this survey. Despite these limitations, our results continue to support 
our hypothesis that these infants possess germline variability in leukemia-associated genes and 
pathways that may reduce the amount of functional somatic mutation typically observed in other 
cancers. 
Given the large number of variants observed, particularly in AML patients, we are not suggesting 
that every variant identified is involved in leukemogenesis, nor that acquired chromosomal 
rearrangements or somatic mutations are irrelevant. We are providing evidence that these infants 
harbor an abundance of congenital and putatively functional variation that may drive or modulate 
early leukemogenesis. Figure 2.4 qualitatively depicts that approximately three to five genes are 
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commonly variant in the germline of most or all of these infants, consistent with the functional 
classes of genes and number (two to eight) of variants, thought necessary for carcinogenesis17. 
This model of germline variation influencing leukemogenesis could explain the short latency that 
has proven difficult to replicate in animal models. The model would not exclude potential 
leukemogenic effects of topoisomerase II inhibitor exposure, although this has only been 
associated with KMT2A-R+ IL, and would also be consistent with the lack of heritability 
observed within pedigrees if co-segregation of many alleles were necessary to predispose to 
malignancy. A recent Brazilian study of leukemia in children younger than 2 years found a 
statistically significant increase in adjusted odds ratios of 1.66 for infants with ALL and a near-
significant increase of 1.54 for AML when any second-degree relative had cancer, supporting the 
conclusion of more subtle familial genetic susceptibility in IL107. Interestingly, the odds ratios 
increased significantly when the children’s father had any cancer (1.80 ALL and 2.34 AML), but 
no such significant increase was observed when mothers had cancer. 
Additive germline variation could also explain the very high concordance observed in 
monochorionic twins as both would have the same profile of inherited genetic variation, as well 
as the relative lack of disease concordance between dichorionic twins despite an 8% incidence of 
shared placental circulation. The ‘intraplacental metastasis hypothesis108’ is useful to describe the 
exceptionally high rate of leukemia concordance for monochorionic twins who share intra-
placental anastomoses. The blood-borne nature of these hematologic malignancies would also 
explain why other pediatric cancer types do not show similarly high concordance in 
monozygotic, monochorionic twins109. However, the majority of twins are dichorionic, and 
approximately 8% demonstrate blood group chimerism because of placental fusion allowing 
blood exchange110. Despite this frequency and multiple reports of twin–twin transfusion 
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syndrome in dichorionic twins111–114, we found only one report of concordant IL in dichorionic 
twins because of the leukemia clone passing between infants, not through inter-placental 
anastomosis, but through the maternal circulation and not resulting in leukemia in the mother, 
only the other twin115. Although discordant IL in monozygotic twins is rare, Brown and 
colleagues documented the apparent spontaneous resolution, potentially through an immune-
mediated process, of a KMT2A-ENL+ clone from a co-twin of an affected twin116. These 
observations further support the conclusion that these circulating leukemic clones require 
additional factors in order to proliferate. 
KMT2C, a homolog of KMT2A, maps to 7q36, which is a chromosomal region often deleted in 
myeloid leukemias117. Like its KMT2 family members, KMT2C is a H3K4 histone 
methyltransferase that regulates gene expression through the FYR and SET domains118. We 
identified nine rare or novel germline frameshift insertions that introduces a premature stop 
codon truncating the C-terminal FYR-N, FYR-C and SET domains (Figure 2.4) necessary for 
proper target gene expression (for example, HOX), critical for embryogenesis and 
development119. KMT2C has not been previously linked to IL, but has been associated with a 
variety of solid tumors and did show an enrichment of mutations in adult AML patients120,121 and 
germline KMT2C variation was recently reported in a pedigree with adult-onset AML and 
colorectal cancer122. In addition to KMT2C, TTN was frequently variable in these patients’ 
germline and has been previously found to carry somatic mutation and germline variation in 
multiple cancer types120,123. Although best studied during embyonal cardiac development during 
mesoderm differentiation between heart and blood, TTN has also been shown to be required for 
proper chromosome packaging and remodeling during cell division124. It is reasonable to 
hypothesize that aberrant chromatin remodeling, either through dysfunctional KMT2C alone or 
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in concert with dysfunctional TTN during embryonal mesodermal differentiation, may have a 
crucial role in the etiology of IL in these KMT2A-R− cases. 
These data raise interesting new insights into the genetic architecture of KMT2A-R− IL. Future 
work will focus on additional sequencing of nuclear family pedigrees with an affected infant to 
further refine the candidate genes influencing leukemogenesis, as well as functional analyses in 
patient-derived myeloid precursors of profiles of additive variation in the context of KMT2C and 
TTN dysfunction within iPSC-based in vitro and in vivo model systems. 
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Figure 2.1: Permuation Testing in IL Exomes. Random permutation testing of gene subgroups 
in IL ALL and AML patients. The distribution of novel, non-synonymous, deleterious variants in 
each figure was generated by randomly selecting either 126 (ALL infants) or 655 (AML infants) 
genes from the patient exomes. The red dot in each panel marks the actual variation observed in 
each patient group (ALL P=3.6 e-5; AML P=1.0 e-38) from each COSMIC candidate gene set. 
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Figure 2.2: The Top 50 Variant ALL and AML Genes in Infants and Mothers. Each row 
indicates an individual and the row position indicates matched pairs (e.g. the top row for ALL 
infants is the child matched to the mother in the top row of ALL mothers). A colored square 
indicates a novel, non-synonymous, deleterious variant in that individual in that gene. The 
shading for each box indicates the number of variants according to the key under the images 
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Figure 2.3: Permutation Analysis in Maternal Exomes. Random permutation testing in 
maternal exomes. The distribution of rare, non-synonymous, deleterious variants in each figure 
was generated by randomly selecting either 126 (for ALL) or 655 (for AML) sets of genes in 
100,000 iterations from the maternal exomes. The red dot in each panel marks the variation 
observed in each maternal group from each COSMIC candidate gene set. Maternal exomes 
demonstrate an enrichment of variation in leukemia-associated genes similarly, but to a lesser 
degree than their infants with acute leukemia. 
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Figure 2.4: Plot of KMT2C Functional Domains and Positions of Germline Sequence 
Variation. The bar represents the coding sequence of the KMT2C open reading frame with 
color-coded functional domains in their relative positions. The circles above the bar represent 
base positions where either missense (blue) or nonsense (red) variants were identified by exome 
sequencing. Nine infants possessed rare nonsense variants (six at the same base position, 
rs150073007). Four of these nine nonsense variants were also observed in the matching infants’ 
mothers 
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Table 2.1: COSMIC defined candidate genes for AML and ALL. 
ALL Candidate Gene List 
ABCC9 CARD11 CTNNB1 ETF1 IDH1 MEGF10 OFD1 PRX STOML2 WDR88 
ADAMTSL3 CBL CYLD EZH2 IGSF5 MLH1 OR51D1 PTEN STRADA ZFHX3 
ADCK1 CCND3 DCC FBXO31 IKZF1 KMT2D OR8H3 PTPN11 SYNE1 ZNF311 
AFF2 CD36 DCHS1 FBXW7 IL7R MSH2 PAX5 RASGEF1A TET2 ZNF394 
AKAP8 CD74 DENND3 FKBP9 JAK1 MTMR8 PCDHB10 RB1 TLL2 ZNF521 
ANKLE2 CD79B DHX15 FLT3 JAK2 MYD88 PDCD4 RGAG1 TSPAN7 ZWILCH 
ARHGEF2 CDC42EP1 DPF2 GBP6 KLF2 MYOM2 PDE6A RUNX1 TMEM30A  
ATM CDKN2A DPYD PAXBP1 KRAS NCEH1 PHOX2A RYR1 TNFAIP3  
B2M CDKN2C DSC3 GIMAP5 LRP1B NEMF PIK3CA SCNN1A TP53  
BCL2L10 COL4A6 DUSP27 ADGRG4 MAGEC3 NF1 PIK3R1 SERPINA1 TRAF3  
BRAF CPNE7 DUSP9 HLA-DMB MDN1 NOTCH1 PMS1 SERPINA6 TSC22D1  
BRSK1 CREBBP ENAM HMGB1 MED12L NOTCH2 PPP2R5A SMARCB1 TSPAN7  
CAMTA1 CRLF2 EP300 HNF1B MEF2B NRAS PRDM1 SOCS1 UBE2A  
 
AML Candidate Gene List 
ABCA10 CACNA1E DCAF8L1 FBXL18 IDH1 LRRC47 NOS1 PTCH1 SLC17A3 TOP3B 
ABCA13 CACNA2D3 DCHS1 FBXL7 IDH2 LRRN2 NOTCH1 PTEN SLC24A3 TP53 
ABCB11 CADM2 DCLK1 FBXO11 IFIH1 LRWD1 NOTCH2NL PTPN11 SLC25A11 TP53I11 
ABCD2 CALB2 DCT FBXO27 IGHMBP2 LTA4H NOTCH4 PTPRE SLC25A12 TP73 
ABCG8 CALD1 DCTN1 FBXO3 IGSF21 LUZP2 NOX3 PTPRG SLC25A20 TPTE2 
ABL1 CAMTA1 DDHD1 FFAR1 IGSF3 MAGEB1 NPM1 PTPRN SLC26A2 TRAM1L1 
ASIC1 CAPG DDX1 FGL2 IKZF1 MAGI1 NRAS PTPRN2 SLC30A6 TRIM24 
ACSS3 CAPN6 DDX60 FILIP1 IL17RD MAGI2 NRK PTPRT SLC37A2 TRPC1 
ACTA2 CAPS DENND2A FKTN IL1R1 MAP1B NRXN2 PTX4 SLC4A11 TRPC4AP 
ADAM11 CARD11 DHX34 FLG IMP4 MAP2 NSD1 PXDNL SLC51A TRPM4 
ADAM33 CASQ1 DIS3 FLRT2 IMPG2 MAP3K15 NUBP2 RAB17 SMAD4 TSPYL5 
ADAMTSL1 CBL DLGAP3 FLT3 INS MAPK1 NUMA1 RAB25 SMARCB1 TTC39A 
AFF2 CCND3 DLX3 FNDC1 INS-IGF2 MASP1 NYX RAB36 SMC1A TTLL10 
AGAP1 CDC42 DNAH3 FOXP1 ITGA8 MAX TENM2 RAD21 SMC3 TTLL2 
AGBL1 CDH18 DNAH5 FREM2 ITGAD MBLAC1 TENM3 RAI2 SMG1 TTLL5 
AHCYL1 CDH24 DNAH9 FRMD8 ITGAX MDFI OVGP1 RANBP2 SOCS1 TTN 
AKAP13 CDH4 DNAJA3 FRMPD3 JAK1 MED14 P2RY2 RASSF7 SOHLH1 TUFT1 
ALS2CR11 CDHR2 DNM2 FRYL JAK2 MEGF11 PA2G4 RB1 SON U2AF1 
AMOT CDKN2A DNMT3A FRZB JAK3 METTL3 PAMR1 RBKS SORCS3 U2AF1L4 
ANG CEACAM19 DOCK2 FZD1 JAM2 MGLL PAPPA2 RBM41 SOS1 UGCG 
ANK3 CEBPA DOCK4 G6PC KDM8 MIER3 PARD3 RBM46 SOX5 UGT1A10 
ANKRD13A CECR2 DOCK9 GABRG3 KAT2B MIS12 PARP2 RBMX SPATA20 UNC5B 
ANKRD26 CELSR1 DOK2 GABRR1 KCNA3 MKRN3 PARP6 RCAN2 SPATS1 UQCR10 
ANPEP CELSR3 DRD2 GANC KCNH5 MKX PCDHA13 RET SPTBN5 USP44 
AP1G2 CEP128 DROSHA GATA1 KCNK6 CENPU PCDHA4 RFC1 SSC4D USP9X 
AP1M1 CEP170 DSCAM GATA2 KCNQ2 MLIP PCDHA6 RGS8 SRRM1 VCAM1 
APOL6 CHIT1 DYNC1H1 GATAD2B KCNQ3 KMT2C PCDHA8 RIMS1 SRRM2 VCAN 
ARC CHRNA4 DYSF GBP4 KCNT1 MORC3 PCDHB1 RIN1 SRSF2 VIL1 
ARHGAP39 CILP2 E2F8 GCAT KCNT2 MPL PCDHB10 RIPK4 SRSF6 VIP 
ARHGAP5 CLCN6 EED GDF10 KDM6A MPND PCDHB11 RNASE9 SSX7 VIPR1 
ARHGEF2 CLVS2 EFL1 GDF5 KHK MRPL14 PCDHB7 RNF111 STAG2 VPS13B 
ARID2 CNGA1 EGFL8 GDPD4 GLTSCR1L MSH6 PCDHGA2 ROBO2 STC2 WAC 
ARSF CNPPD1 EIF2D GDPD5 KIAA1217 MSR1 PCDHGC4 RP1 STK32A WDR11 
ASAP2 CNTLN EIF4B GLE1 NWD2 MTMR8 PCMTD2 RP1L1 STK36 WEE1 
ASTE1 CNTN5 ELANE GLI1 ARFGEF3 MTUS2 PDGFRA RPL27A STRN WLS 
ASTL CNTNAP4 ELF1 GLRA1 KANSL1 MYBL2 PDK4 RPL9 STT3B WNK4 
ASXL1 CNTRL ELFN2 GLTPD2 KIDINS220 MYCBP2 PDLIM7 RSRC2 STX3 WT1 
ATG16L1 COL11A2 ELL GNAI2 KIF2C MYEOV PDS5B RUFY1 STXBP2 XIRP1 
ATM COL12A1 ELN GNB1 KIT MYH14 PDXDC1 RUNX1 SULT1C2 ZC3H12D 
ATP1A2 COL19A1 EML4 GPC2 KLHL29 MYLK2 PGLYRP2 RXFP1 SUPT5H ZC3H18 
ATP1B4 COL27A1 ENC1 GPR183 KLK7 MYO18B PHF6 SAA4 SUSD5 ZC3H8 
ATP2A2 COL2A1 EPB41L5 ADGRV1 KRAS MYO1F PHF8 SAP130 SUZ12 ZDHHC11 
ATP6V1G3 COL7A1 EPHA8 GPRC6A KRT1 MYOC PKD1L2 SCARB1 SV2A ZFHX2 
ATP9B COL9A1 EPHB1 GRIK2 KRT14 NAE1 PKD1L3 SCEL SYTL4 ZFHX3 
B4GALNT1 COMMD5 ETF1 GRIN2B KRT79 NALCN PKD2L1 SCML2 TACR3 ZMYND8 
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BAAT CP ETV6 GRIP1 KSR2 NANOS2 PKHD1 SCUBE3 TBC1D4 ZNF211 
BABAM1 CPLX4 EVPL GRM8 L1CAM NAPA PLCH2 SDK2 TBX5 ZNF213 
ADGRB1 CREBBP EWSR1 GSTM3 LAMA5 NAT8L PLCZ1 SEMA3A TCEAL3 ZNF236 
BBS7 CSF1R EXOC2 GUCA1A LAMC1 NAV1 PLIN1 SEMA7A TCOF1 ZNF260 
BCL11B CTCF EXOC4 GUCA2A LARP4B NCAPH PLRG1 14-Sep TCTE3 ZNF276 
BCLAF1 CTSG EZH2 HERC1 LCE1B NCOA7 PLXNA3 SEZ6L TET2 ZNF324B 
BCOR CUBN EZR HIVEP1 LIMA1 NCR1 PNPLA7 SF3B1 THEG ZNF34 
BECN1 CUL3 AMER2 HJURP LIPC NDST3 POLR2A SFXN2 TRIM24 ZNF37A 
BICD1 CYBB FAM13A HK1 LIX1 NDUFA13 POU6F2 SH3TC2 TKTL1 ZNF43 
BMP5 CYLC1 FAM171A1 HKDC1 LONRF1 NEFH PPP1R9A SHANK1 DCSTAMP ZNF462 
BMPER CYP1A2 FAM19A4 HMCN1 LPL NEMF PRDM9 SHQ1 TMEM132C ZNF485 
BMS1 CYP4F8 FAM27E5 HNRNPUL1 LRIG3 NES PRICKLE3 SHROOM2 TMEM151B ZNF616 
BOC DAAM2 FAM57B HOOK3 LRP1B NF1 PRODH2 SI TMEM169 ZNF677 
BPTF DAGLA BRINP3 HRCT1 LRP4 NF2 PRPF40B SIGLEC1 TMEM198 ZNF687 
BRAF DAGLB FAM69A HTR1A LRRC2 NLRP4 PRPF8 SIMC1 TMTC2 ZNF689 
BRPF1 DAOA FAM83B HTR3C LRRC37A3 NLRP8 PRR13 SKOR1 TNKS1BP1 ZNF75D 
BRWD3 DAXX FANCI HTR5A LRRC37B NMNAT2 PRSS27 SLC12A1 TNR ZNF788 
BTBD8 DAZAP2 FBN2 HYDIN LRRC40 NONO PSG3 SLC15A1 TNS4 ZRSR2 
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Table 2.2: Validation of called exome variants via dideoxy sequencing. Fifty rare, single 
individual variants with ≥5-fold coverage and a quality score ≥20 were selected for secondary 
dideoxy validation. Of the 50, 43 (86%) were validated and are listed here. Rare variants 
observed in both mother and child were not chosen for validation as they are unlikely to be false 
positives. 
 
Gene Position (hg19) Subject with 
Variant
Reference Base Variant Allele AA change Forward primer Reverse primer
AFF2 chrX:148035259 Infant C T GCA (A) è GTA (V) cacctgaactgggctgtttt ctggcaccttcactcacctc
AIF1 chr6:31584079 Infant G C AGG (R) è ACG (T) ttggtgagaaacgggtgatttgcggg ttgagcctgtggacaagggtagggat
ALDOA chr16:30078672 Infant G A GCA (A) è ACA (T) taccaatatccagcactgaccccgga tgttctcggtgccaatggactgca
ATXN7L1 chr7:105255128 Infant C G AGG (R) è AGC (S) atgagggaaagctgtggtgtgggaca agcaatgccaacccgatgtctcact
COL16A1 chr1:32156158 Infant G C CCA (P) è CGA (R) cttcacacctggcttcccctgtta ctcccttcctttgaaacctagaatggct
COPA chr1:160262988 Infant T C ACT (I) è GTC (V) ccccttatgggtaggataatttcccttg cggcagggatgagtggctaatactt
DDX43 chr6:74104671 Infant G A GTT (V) è ATT (I) tggcacgctactcttacgacgtca caaaacacagcggcagttcctcgt
EEF1G chr11:62339051 Infant C T TGG (W) è TGA (stop) acagacacttcctccatcaactgccc tttggaggtgagggtgtaggagagga
EFTUD chr15:82533640 Infant G A GTA (V) è ATA (I) cccctctttcctcacccttaaccatt tgggaaaagttggaatggtagctctgg
EXOC3 chr5:465833 Infant G C GGT (G) è CGT (R) tgaagagggaggttcccagtcaggaa cgtgcatcccttacctgatgtctgga
FAM196B chr5:169310673 Infant G C GGG (G) è GCG (A) actggctgtgagtctcttccttttga agtgtatggtcctgatccttcccact
GBA2 chr9:35739005 Infant C A GAC (D) è TAC (Y) ggagccatggttcatcatctgtggga attccctgcctcccttctgtgtctct
GPR84 chr12:54756704 Infant G A TCA (S) è TTA (L) tgcaaccattgagccaggtgaggtt acaggcaagcatccactccaacca
KCNIP4 chr4:20852245 Infant G C CCT (P) è GCT (A) ctctgggaattgtgtgaaggta tccgttttcctttgttgctc
KIF11 chr10:94389974 Infant G T CAG (Q) è CAT (H) actagctagatatcctaccagccagct tggcagcatcatgaagtttctcctca
LILRA3 chr19:54802548 Infant G T TCC (S) è TAC (Y) tgtcactgtctgtctctccctccctt agggaaagtttgtggggaagcctga
NCAPD3 chr11:134062612 Infant C T CTC (L) è TTC (F) tggaagtcagtcagggaaagagagacca agatgcgtgcagatccagaaagcct
NCOA2 chr8:71041055 Infant C G CGG (R) è CCG (P) gtcttagttgatttggctggttctgcac tccagagccaagcagtagatccaga
OR2V2 chr5:180582262 Infant GTCT deletion Frameshift ttcttcctcagccagctctccctcat accttcctcaagccacagtaggggaa
PHKB chr16:47684830 Infant C A CAG (Q) è AAG (K) tgaacacagtgagcccttgggaaga tgctgcaagtgttcaagcatctgact
PIP4K2C chr12:57992903 Infant G A CGA (R) è CAA (Q) tccctgggctgtttgtgtatctgct aaagaacagtcagaacccagcccct
POLR3A chr10:79773461 Infant G T CTT (L) è ATT (I) tggcgttgttagttgtggtggtgtt agtgcccagtattccaggaagccat
PRDM7 chr16:90142285 Infant G A GAA (E) è AAA (K) ccccattccaatgcacattcagacaga agtcttcctgctctgaacacccca
PRRC2C chr1:171509954 Infant G C GTA (V) è CTA (L) agcaccaattcagccacagtcagtt ggcctcgacctctgtatccttgatct
PTGES3L chr17:41123653 Infant C T GAG (E) è AAG (K) tcctccagagacatgtgtgcagaga atatgcccacactctcccacacact
RALGAPA2 chr20:20506962 Infant C G CAG (Q) è CAC (H) cctctgtctggaatactgctggctt acacagtgaggctagagaagagacagt
RRAD chr16:66957510 Infant G C CAG (Q) è CAC (H) ttccctccccgccagttttctttct tgtgtgttgtgtgttctccaggacgg
SFTPA2 chr10:81317038 Infant C T GGC (G) è AGC (S) acacactgctcttttccccgacct tgcagggctccataatgacagtagga
SYNE1 chr6:152469381 Infant G A GAG (L)èGAA (E) gggatggagtccacactagc ctagctcccagacgatgagc
SYNE1 chr6:152570334 Infant C A TGC (A)èTGA (stop) caaacaaaagtgccactgtga tgagttttcccgttgctttc
SYNE1 chr6:152576794 Infant C T TTC (E)èTTT (F) aaaagtgctgtggcaacaaa ggccccatcctgatattttt
SYNE1 chr6:152631566 Mother G A ACG (R)èACA (T) gcttacctgccgatgagaga tgctcacctgtgatgtggtt
SYNE1 chr6:152631653 Infant C A ATC (D)èATA (I) gcttacctgccgatgagaga tgctcacctgtgatgtggtt
SYNE1 chr6:152642398 Mother G A CGC (A)èCAC (H) tcacacaagaggactgacccta ccacaaatcaccgacagaac
SYNE1 chr6:152650962 Infant G C TGT (T)èTCT (S) tcagcgaggctgtgttctaa acctcaacctgcaggacatc
SYNE1 chr6:152674464 Mother C A CTT (K)èATT (I) tgcctacctccaacgtcttc ctggcacaggcctttacttc
TRPV4 chr12:110230503 Infant G C ACC (T) è AGC (S) atgtggtgtgtgtgtgactccctcca tgtcttcccctccagagcctcattgt
TXNIP chr1:145440753 Infant G A AGT (S) è AAT (N) tgttaccacagctgtcttgtttctccag ccacataagaatcctgcccaagaaatgc
UGT3A2 chr5:36039780 Infant C G GAC (D) è CAC (H) tgggccaatgagaacactgacactt aggacatgaccacagtgcagctagt
ZHFX3 chr16:72830465 Infant G A TGG (P)èTAG (stop) ggtgcaattgtaggtgaggtg tcaagagcacgttcatcagaa
ZHFX3 chr16:72832557 Mother C T TCC (G)èTCT (S) ctgaccggttgctgattctt ggtgccatccttgaaacaaa
ZNF362 chr1:33764618 Infant G C GGC (G) è CGC (R) tccctgttctgaatctcatccctgc tctggaagattgggaaggtcgtgag
ZNF717 chr3:75788130 Infant C T GGG (G) è GAG (E) ctctcctgtgtgtgtctgctgatgt accaacagcaacacatcaactcagga
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Table 2.3: Demographic characteristics of the study cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ALL AML
Sex   Boys 4 6
  Girls 8 7
8.3           
(0.6 - 11.4)
5.3             
(1.6 - 11.4)
31.9       
(21.3-40.6)
33.4      
(25.4-41.8)
3 5
Avg maternal age 
(years)
No. mothers >35 yrs
Avg age at diagnosis 
(months)
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Table 2.4: The average and range of filtered variants per exome in each subgroup. Total exomic 
variants (single nucleotide variants and INDELs) were filtered for variants that were novel (not 
previously included in dbSNP 135 and the 1,000 Genomes Project), non-synonymous, with 
coverage ≥5-fold, a genotype quality score ≥10 and a mapping quality score of ≥60. 
 
 
Average total variants per 
exome Range 
ALL infants 1,264.4 463 – 3,209 
ALL mothers 1,112.6 985 – 1,267 
AML infants 2,549.9 519 – 5,545 
AML mothers 1,225.0 1,000 – 1,660 
Unaffected controls 582.8 467 – 719 
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Table 2.5: Hypergeometric analysis of variation in leukemia-associated genes determined by 
comparing the observed amount of RNS variation in the 126 (ALL) or 655 (AML) COSMIC-
identified candidate genes against the expected amount of similar sequence variation observed by 
randomly selecting 126 or 655 genes from the same patients. P-values generated from 
hypergeometric (Fisher’s Exact) test with α = 0.005 (* = not significant). 
 Group 
Average 
variants / 
exome 
Range P-value* 
 ALL infants 12.1 3 – 33 3.6 e-5 
ALL genes 
(n = 126) 
ALL mothers 6.4 3 – 11 1.4 e-3 
Unaffected 
controls 
1.9 0 – 4 0.24* 
AML infants 22.7 4 – 37 3.0 e-9 
AML mothers 8.2 4 – 16 1.7 e-9 
 AML infants 163.4 38 – 358 1.0 e-38 
AML genes     
(n = 655) 
AML mothers 132.5 60 – 667 5.3 e-19 
Unaffected 
controls 
27.5 12 – 37 0.007* 
ALL infants 59.4 24 – 131 5.2 e-29 
ALL mothers 49.6 40 – 67 1.5 e-11 
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Table 2.6: The likelihood of possessing as RNS variant in a leukemia-associated gene. Likelihood 
ratios were calculated as follows:  
Number of rare, non-synonymous, deleterious variants (either ALL or AML mothers or infants) / total number of variants in the 
respective group 
Number of rare, non-synonymous, deleterious variants in controls / total number of variants in controls 
 
Leukemia subtype Subgroup 
Likelihood ratio of having a 
rare, non-synonymous, 
deleterious variant in a 
COSMIC-defined candidate 
gene relative to controls. 
ALL Infants 2.01 Mothers 1.62 
AML Infants 1.44 Mothers 1.44 
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Table 2.7: Individual variant listings for each RNS variant called variants with ≥5-fold coverage, 
a genotype quality score of ≥10, and a mapping quality score of ≥60 (see Methods) in the top 
three most commonly variable genes from the AML-candidate gene list (see Figure 2, Panel B). 
Each row lists an individual variant by gene, position (hg19), frequency in the infant exomes, 
frequency in the maternal exomes, and the dbSNP identification number (if applicable, blank 
means the variant is novel). 
 
Gene Position
Infant 
Frequency
Mother 
Frequency dbSNP
 ID Gene Position Infant Frequency
Mother 
Frequency dbSNP
 ID
TTN chr2:179393490 14% 0% TTN chr2:179392343 13% 0%
TTN chr2:179395413 14% 0% TTN chr2:179393346 0% 10%
TTN chr2:179413687 14% 0% TTN chr2:179404199 13% 0%
TTN chr2:179414436 14% 0% TTN chr2:179413565 13% 0%
TTN chr2:179414817 14% 0% TTN chr2:179422215 13% 0%
TTN chr2:179415929 14% 0% TTN chr2:179425264 0% 10%
TTN chr2:179416935 0% 10% TTN chr2:179427497 13% 0%
TTN chr2:179417152 0% 10% TTN chr2:179429150 13% 0%
TTN chr2:179417452 14% 0% TTN chr2:179432641 13% 0%
TTN chr2:179419226 0% 10% TTN chr2:179434267 13% 0%
TTN chr2:179421596 14% 0% TTN chr2:179436754 13% 0%
TTN chr2:179421791 0% 10% rs183013408 TTN chr2:179441457 13% 0%
TTN chr2:179422214 14% 0% TTN chr2:179455560 13% 0%
TTN chr2:179424856 14% 0% TTN chr2:179458072 13% 0%
TTN chr2:179432185 14% 10% TTN chr2:179460461 13% 0%
TTN chr2:179433832 14% 0% TTN chr2:179462635 0% 10%
TTN chr2:179434798 14% 0% TTN chr2:179474277 0% 10%
TTN chr2:179435903 0% 10% TTN chr2:179481277 13% 0%
TTN chr2:179437494 14% 0% TTN chr2:179482201 13% 0%
TTN chr2:179439611 14% 0% TTN chr2:179485631 0% 10%
TTN chr2:179440635 14% 0% TTN chr2:179494968 0% 10% rs192766485
TTN chr2:179440995 14% 0% TTN chr2:179500768 0% 10%
TTN chr2:179444512 14% 0% TTN chr2:179553427 13% 0%
TTN chr2:179444789 14% 0% TTN chr2:179566946 0% 10%
TTN chr2:179447898 0% 10% TTN chr2:179570047 0% 10%
TTN chr2:179449116 0% 10% TTN chr2:179572323 0% 10%
TTN chr2:179453343 14% 10% rs191549948 TTN chr2:179582796 13% 0%
TTN chr2:179455677 0% 10% TTN chr2:179594134 13% 0%
TTN chr2:179456083 14% 0% TTN chr2:179596188 13% 0%
TTN chr2:179458118 14% 0% TTN chr2:179599069 13% 0%
TTN chr2:179458151 14% 0% TTN chr2:179599521 13% 0%
TTN chr2:179464371 14% 0% TTN chr2:179600264 13% 0%
TTN chr2:179466511 14% 0% TTN chr2:179604611 13% 0%
TTN chr2:179469558 14% 0% TTN chr2:179605815 0% 10% rs201888760
TTN chr2:179473055 14% 0% TTN chr2:179614489 13% 0%
TTN chr2:179473455 0% 10% TTN chr2:179614883 13% 0%
TTN chr2:179476243 0% 10% TTN chr2:179615326 13% 0% rs142848087
TTN chr2:179476610 14% 0% TTN chr2:179632544 13% 0%
TTN chr2:179483493 14% 0% TTN chr2:179634421 25% 40% rs200875815
TTN chr2:179483524 14% 0% TTN chr2:179636009 0% 10%
TTN chr2:179486004 14% 0% TTN chr2:179650587 0% 10% rs199507913
TTN chr2:179501253 14% 0% TTN chr2:179650627 13% 0%
TTN chr2:179504807 14% 0% TTN chr2:179664619 13% 0%
TTN chr2:179516237 14% 0% RBMX chrX:135956408 75% 70% rs76876438
TTN chr2:179535890 14% 0% RBMX chrX:135956462 50% 50% rs74463481
TTN chr2:179549399 14% 0% RBMX chrX:135956506 50% 40% rs77794331
TTN chr2:179571461 14% 0% RBMX chrX:135956573 50% 10%
TTN chr2:179575569 14% 0% RBMX chrX:135957672 0% 10% rs139356075
TTN chr2:179583286 14% 0% RBMX chrX:135957690 0% 10% rs150541875
TTN chr2:179587640 14% 0% RBMX chrX:135957700 0% 10% rs139954333
TTN chr2:179590307 14% 0% RBMX chrX:135957716 0% 10% rs142284545
TTN chr2:179594158 14% 0% RBMX chrX:135958704 0% 10% rs112089728
TTN chr2:179594648 14% 0% RBMX chrX:135958730 0% 10% rs78702689
TTN chr2:179594867 14% 0% RBMX chrX:135960119 13% 10% rs76812369
AML Infants ALL Infants
Variant list for the top three variant AML-candidate genes (see Figure2, Panel B) - page 1 of 2
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Gene Position
Infant 
Frequency
Mother 
Frequency
dbSNP ID Gene Position Infant 
Frequency
Mother 
Frequency
dbSNP ID
TTN chr2:179594933 14% 0% RBMX chrX:135960147 50% 20%
TTN chr2:179595693 0% 10% RBMX chrX:135961560 13% 10% rs80321628
TTN chr2:179599124 14% 0% RBMX chrX:135961585 0% 10%
TTN chr2:179600360 14% 0% MLL3 chr7:151842305 13% 0%
TTN chr2:179605985 14% 0% MLL3 chr7:151860230 0% 10% rs142835638
TTN chr2:179606240 14% 0% MLL3 chr7:151873435 13% 0%
TTN chr2:179610430 14% 0% MLL3 chr7:151902197 0% 10% rs138119145
TTN chr2:179610827 14% 0% MLL3 chr7:151927016 0% 10% rs141049734
TTN chr2:179610922 14% 0% MLL3 chr7:151927025 13% 0% rs183684706
TTN chr2:179610943 14% 0% MLL3 chr7:151932945 25% 10% rs199504848
TTN chr2:179610988 14% 0% MLL3 chr7:151945072 75% 40% rs150073007
TTN chr2:179610989 14% 0% MLL3 chr7:151945228 0% 10% rs200184971
TTN chr2:179611336 0% 10% MLL3 chr7:151960181 13% 0%
TTN chr2:179612343 14% 0% MLL3 chr7:151962265 0% 30% rs201834857
TTN chr2:179613163 14% 0% MLL3 chr7:151970877 13% 0% rs138627563
TTN chr2:179634421 14% 50% rs200875815
TTN chr2:179640696 14% 0%
TTN chr2:179642589 0% 10%
TTN chr2:179659744 0% 10%
TTN chr2:179669360 14% 0%
RBMX chrX:135956408 43% 60% rs76876438
RBMX chrX:135956462 29% 60% rs74463481
RBMX chrX:135956506 29% 40% rs77794331
RBMX chrX:135956573 29% 30%
RBMX chrX:135960147 14% 0%
RBMX chrX:135961560 14% 0% rs80321628
RBMX chrX:135961585 0% 10%
MLL3 chr7:151841869 14% 0%
MLL3 chr7:151875022 14% 0%
MLL3 chr7:151884389 14% 0%
MLL3 chr7:151891103 14% 0%
MLL3 chr7:151902304 14% 0%
MLL3 chr7:151919134 14% 0%
MLL3 chr7:151927025 43% 20% rs183684706
MLL3 chr7:151932945 29% 0% rs199504848
MLL3 chr7:151945072 86% 30% rs150073007
MLL3 chr7:151945225 0% 10% rs202098135
MLL3 chr7:151949795 14% 0%
MLL3 chr7:151962134 0% 10% rs146238849
MLL3 chr7:151962168 0% 10% rs138908625
MLL3 chr7:151962265 0% 10% rs201834857
MLL3 chr7:151970859 14% 0% rs149992209
MLL3 chr7:152012416 14% 0%
MLL3 chr7:152027753 14% 0%
MLL3 chr7:152055740 14% 0%
Variant list for the top three variant AML-candidate genes (see Figure2, Panel B) - page 2 of 2
AML Infants ALL Infants
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Table 2.8: Individual variant listings for each rare, non-synonymous, predicted deleterious 
variant called with ≥5-fold coverage, a genotype quality score of ≥10, and a mapping quality 
score of ≥60 (see Methods) in the top three most commonly variable genes from the ALL-
candidate gene list (see Figure 2, Panel A). Each row lists an individual variant by gene, position 
(hg19), frequency in the infant exomes, frequency in the maternal exomes, and the dbSNP 
identification number (if applicable, blank means the variant is novel). 
 
 
Gene Position
Infant 
Frequency
Mother 
Frequency
dbSNP ID Gene Position Infant 
Frequency
Mother 
Frequency
dbSNP ID
MDN1 chr6:90377741 14% 0% MDN1 chr6:90363929 0% 10%
MDN1 chr6:90383180 14% 0% MDN1 chr6:90363955 13% 0%
MDN1 chr6:90383935 14% 0% MDN1 chr6:90368355 13% 0% rs115792683
MDN1 chr6:90388424 14% 0% MDN1 chr6:90368471 13% 0%
MDN1 chr6:90398446 14% 0% MDN1 chr6:90368490 13% 0%
MDN1 chr6:90405449 0% 10% MDN1 chr6:90372565 13% 0%
MDN1 chr6:90405586 0% 10% MDN1 chr6:90385883 13% 0%
MDN1 chr6:90420493 14% 0% MDN1 chr6:90385922 13% 0%
MDN1 chr6:90424435 0% 10% rs150248107 MDN1 chr6:90396621 13% 0%
MDN1 chr6:90434947 14% 0% MDN1 chr6:90434940 13% 0%
MDN1 chr6:90450026 0% 10% rs114779526 MDN1 chr6:90448168 13% 0%
MDN1 chr6:90459345 14% 0% MDN1 chr6:90504494 13% 0%
MDN1 chr6:90513126 14% 0% SYNE1 chr6:152461288 13% 0%
MDN1 chr6:90513189 0% 10% rs143308656 SYNE1 chr6:152462353 13% 0%
SYNE1 chr6:152443578 14% 0% SYNE1 chr6:152462387 13% 0%
SYNE1 chr6:152563445 14% 0% SYNE1 chr6:152532645 0% 10%
SYNE1 chr6:152570334 14% 0% rs149272010 SYNE1 chr6:152542011 0% 10%
SYNE1 chr6:152576099 0% 10% SYNE1 chr6:152576794 13% 0%
SYNE1 chr6:152577804 14% 0% SYNE1 chr6:152642378 13% 0%
SYNE1 chr6:152631566 14% 10% rs145899734 SYNE1 chr6:152644741 0% 10%
SYNE1 chr6:152642398 0% 10% rs140850000 SYNE1 chr6:152658104 13% 0%
SYNE1 chr6:152688393 14% 0% SYNE1 chr6:152804248 0% 10%
SYNE1 chr6:152720877 14% 0% rs112061681 MLL2 chr12:49425964 0% 10% rs200315963
SYNE1 chr6:152737745 14% 0% MLL2 chr12:49426773 13% 0%
SYNE1 chr6:152763314 14% 0% MLL2 chr12:49428694 0% 10% rs146044282
SYNE1 chr6:152771967 0% 10% rs141464488 MLL2 chr12:49432416 0% 10%
SYNE1 chr6:152777056 14% 0% MLL2 chr12:49433599 0% 10% rs147706410
SYNE1 chr6:152787119 14% 0% MLL2 chr12:49434934 0% 10%
MLL2 chr12:49418376 14% 0% MLL2 chr12:49435457 0% 10%
MLL2 chr12:49420207 0% 10% MLL2 chr12:49441813 13% 0%
MLL2 chr12:49421675 14% 0%
MLL2 chr12:49425287 0% 10%
MLL2 chr12:49426100 0% 10%
MLL2 chr12:49436413 14% 0%
MLL2 chr12:49443500 14% 0%
MLL2 chr12:49444031 0% 10%
MLL2 chr12:49444700 14% 0%
MLL2 chr12:49445392 0% 10% rs202076833
MLL2 chr12:49445967 14% 0%
MLL2 chr12:49447294 14% 0%
MLL2 chr12:49448150 14% 0%
Variant list for the top three variant ALL-candidate genes (see Figure2, Panel A) - page 1 of 1
AML Infants ALL Infants
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3. Later Sequencing 
3.1 Introduction 
Our early sequencing results showed a clear enrichment of putatively damaging variation in 
known leukemia associated genes.  The similar, but less pronounced enrichment that was present 
in the mothers of these infants suggests that there is a threshold of variation that needs to be 
reached, or that additional insults, likely during a narrow developmental window, are required to 
turn the observed enrichment of variation into frank leukemia.  While the initial sequencing 
studies that we performed were done as rigorously as possible at the time, there were a number 
of weaknesses present. The small sample size, an inevitable consequence of the rarity of the 
disease and our focus on KMT2A-R- leukemia, limited the power of our analyses and the scope 
of investigation that we could perform. The 1000 genomes database was used for filtering and 
quality control. At the time, this resource was the best available, but in the years that followed, a 
number of resources replaced it, most notably the exome aggregation consortium (ExAC) 
database125. Similarly, the best practices for exome sequence data processing, controls and 
analysis have also matured126. 
In the sequencing results in this chapter, we address these shortcomings, and present a greatly 
expanded analysis of the germline variation present in IL patients. Importantly, we greatly 
increase our samples size, sequence controls in the same workflow, employ the powerful ExAC 
database to filter and curate our variants, and expand beyond candidate gene lists to discover new 
genes that are more highly variant in IL patients 
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3.2 Methods 
3.2.1 Samples 
DNA samples were collected from infants with KMT2A-R+ acute leukemia who were enrolled 
on the COG-AE24: ‘Epidemiology of Infant Leukemia’ protocol as described previously in 
section 2.2. 
DNA from an additional 8 IL patients was obtained from the Children’s Hospital of Westmead. 
Sequencing and analysis of these samples was performed as described for the AE24 cohort. 
Additionally, 22 full genome sequences from the Pediatric Cancer Genome Project (PCGP), a 
collaboration between Washington University in St Louis and St. Judes Hospital, were obtained 
from dbGAP. 
As a control, fourteen individual exomes were generated from DNA obtained from the Nurse’s 
Health Study.  These were all from healthy adults with no known history of cancer.  
Individual level data from 77 participants in the 1000 Genomes Project127 were used as 
additional controls in some analyses. 
3.2.2 Exome Sequencing 
As these sequencing studies were performed over several years, a variety of exome library kits 
were used. All of these kits were used according to manufacturer instructions.  The various kits 
used are: Illumina TruSeq Nano DNA library preparation kit, Illumina TruSeq DNA Sample 
Prep v2 kit. Library preparation was followed by hybridization capture of each exome according 
to the Illumina TruSeq Exome Enrichment Kit (Illumina, San Diego, CA USA) or the IDT xGen 
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exome research panel. Sequencing was performed on Illumina 2500, HiSeq or NovaSeq 
machines. 
3.2.3 Analysis pipeline 
Raw reads were aligned to the hg19 reference genome using bowtie-2 using options –N 1 –X 
2000 –p 8.  The resulting .sam file is sorted and indexed using samtools96.  Duplicates are 
marked and removed using samtools. The GATK indelRealigner is used to realign around 
spurious indel sites128.  The resulting .bam file is used as input to samtools mpileup for variant 
calling using options –q 5 –Q 15. Variants were filtered using awk to retain only the variants 
called in positions with 5 or more reads, and quality scores >= 10.  Further filtering and 
annotation was performed using the variantsReduction.pl tool from the ANNOVAR software 
package97. This step kept only variants that introduced non-synonymous coding changes, splice 
site changes, or changes in the UTR. Further, variants present at >0.01 MAF in the ExAC125 
database were discarded.  The resulting rare, non-synonymous (RNS) variants were enriched for 
putatively functional variation.  Further manual curation of candidate and target genes was 
performed to ensure that only the highest quality variants were retained.  Specifically, any 
variant that did not pass the VQSRTranche, Adj_AC, or Inbreeding_Coeff_filter in ExAC were 
discarded. 
3.2.4 Statistical Analyses 
An initial analysis that used the same hypergeometric testing for enrichment of deleterious 
variation in COSMIC genes was performed as previously described.  
To observe the differences in the frequency of rare variation in all genes across the exome, the 
number of variant alleles for each gene in each sample (i.e. IL patients, NHS controls, EVS 
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samples or ExAC samples) was counted.  This number was then divided by the number of alleles 
sequenced in that sample. The resulting frequencies were plotted using R (version 3.2.1; 
available at http://www.r-project.org).  A linear model of the resulting scatterplot was fit using 
the lm package in R. All genes that were more than five standard deviations from the regression 
line were deemed “highly variable.”  This list of highly variable genes contained a large number 
of seemingly spurious genes (eg. Olfactory receptors, mucin genes).  To ensure that only the 
genes that were most likely to contribute to IL were retained, this list was filtered to keep only 
the genes that were “Loss-of-function intolerant” as defined by ExAC, as well as the genes that 
were not also highly variant in control samples.  The resulting gene list was used for downstream 
analysis. 
3.3 Results 
This new cohort of IL exomes was much larger than the original focused KMT2A-R- study we 
performed. As a first pass, and to validate our previous findings, we performed the same 
hypergeometric test to determine whether there was an enrichment of rare, non-synonymous 
variation in known leukemia-associated genes.  As expected, we observed a marked enrichment 
regardless of KMT2A-R status or leukemia type (Table 3.1).  This was an encouraging finding, 
especially since our improved filtering strategy had removed many more variants than had been 
previously. Notably, some of the most frequently observed variants in KMT2C when filtered by 
1000 genomes, were found to be spurious when the much larger ExAC database was used as a 
filter. Despite this, though, there was still a marked enrichment of RNS variants in leukemia-
associated genes in all IL subsets, but not in controls.   
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Given the much greater power afforded by this larger cohort, we next expanded our interrogation 
from a short list of genes selected a priori to the entire genome. To do this we tallied the number 
of RNS variant alleles in each gene for a given cohort, and divided it by the number of alleles 
sequenced in that cohort. To ensure that this method was reliable, we first compared this measure 
of variation for each gene in ExAC to the same measure calculated from the Exome Variant 
Server (EVS) (Figure 3.1)129.  As expected, there is a very strong linear relationship between 
these databases.  This analysis makes it clear that while there is a wide range in this measure 
between genes, it is largely consistent for a given gene between similar populations. The 
variability between genes will be a function of evolutionary constraint (or lack thereof), gene 
size, variable mutation rates based on genomic location130,131 and possibly other factors. These 
factors, though, will be acting in roughly the same way in different groups, provided these 
groups are similar in makeup. Hence, when comparing the variation in every allele from the EVS 
to every allele in ExAC, we see that the variation present in a given gene is relatively constant. 
This relationship is largely preserved when comparing between our control exomes and ExAC 
(Figure 3.2). Due to the much smaller sample size, a few genes appear to have much higher 
variation in our control exomes than in ExAC. While we expected this to occur due to random 
fluctuations present in the small sample, we wanted to ensure that this “enrichment” was indeed 
random. To do this, we applied a filter based on the “Loss-of-function (LoF) intolerance” 
measure developed by ExAC. Briefly, this scores each gene based on the ratio of the number of 
possible LoF variants to the number of observed LoF variants. This ratio is calculated for each 
gene, and genes in the top 10% (i.e. those with the far fewer observed LoF variants than 
expected) are deemed LoF intolerant. When we filtered the “enriched” genes in the control 
exomes, we saw that very few of them were LoF intolerant.  Further supporting the fact that they 
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are artifacts, we see that many of them are extremely large genes and enriched for olfactory 
receptors and mucin genes, all of which tend to have increased artifacts131. 
We then compared our IL exomes to ExAC using the same measure. Again, we see that RNS 
variation in several genes that are markedly elevated in IL relative to ExAC (Figure 3.3). 
However, unlike the control exomes, many of these genes are LoF intolerant.  Indeed, many of 
the genes that did not pass the LoF-intolerance filter are shared between the control and IL 
exomes, further supporting their artifact status. In addition to these artifacts, however, a large 
number of LoF intolerant genes have far more RNS variation in IL patients than in the ExAC 
cohort. Presumably, this group is enriched for genes that contribute to the development of IL.  
When we explored the genes that comprised this group, a number of patterns emerged.  First, 
KMT2C and KMT2B were both present.  This corroborates our finding in the initial KMT2A-R- 
cohort, and, when considered along with the frequency of KMT2A-rearrangements in IL, makes 
a strong argument for the critical role of KMT2 genes in infant leukemogenesis. We further 
explored this idea with a direct interrogation of each KMT2 gene. The KMT2 genes each anchor 
a complex of proteins known as COMPASS complexes (COMplex of Proteins ASsociated with 
SET)132. Since the function of these gene products will rely, at least in part, on the function of the 
complexes that they anchor, we also included known members of COMPASS complexes in this 
analysis. Indeed, there is a significant enrichment of RNS variation in these genes in IL patients 
regardless of KMT2A-rearrangement status relative to control exomes, 1000 genomes 
participants and ExAC (Figs 3.4 and 3.5). Interestingly, patients with KMT2A-R+ leukemia had 
relatively less RNS variation in KMT2A and KMT2B than did patients with KMT2A-R- 
leukemia.  Conversely, KMT2A-R+ patients tended to have less RNS variation in KMT2C and 
KMT2D than their KMT2A-R- counterparts. While not conclusive, these data are consistent with 
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the hypothesis that dysfunction of both KMT2A/KMT2B complex genes and KMT2C/KMT2D 
complex genes is an important feature of IL. This dysfunction can arise through germline 
variation in either complex, but the requirement for germline variation in the KMT2A/KMT2B 
complex is abrogated in the presence of a somatically acquired KMT2A rearrangement. 
Regardless of whether concurrent dysfunction in both of these complexes is a requirement for IL, 
it seems clear that the KMT2 family of genes play an important role in this disease. 
In addition to KMT2B and KMT2C, there were many other genes present in the RNS variant-
enriched group (Table 3.2). Interestingly, many of these genes have similar biological functions. 
Genes encoding ubiquitin ligases, transcriptional modifiers and RNA binding proteins in 
particular seemed to capture the majority of this group. There were also a number of genes with a 
previously known link to leukemia (e.g. PTEN). As a group, these genes provide strong clues 
about the processes that may lead to IL and provide an excellent set of candidates for functional 
studies. 
It is unlikely that any single gene is responsible for the development of IL. Thus, we next turned 
our attention to the combinations of variants present in each individual. We focused on those 
genes that are enriched for RNS variation relative to ExAC. As seen in Figure 3.5, all IL patients 
have at least one variant in at least one of these genes. So while we have potentially captured 
many of the genes that contribute to infant leukemogenesis, the list presented is likely 
incomplete. It seems much more likely that combinations of multiple RNS variants in multiple 
pathways will be required for the development of IL. Interestingly, there seem to be genes that 
are rarely variant in the same individual. Our sample size is too small to make a strong claim on 
this point, but the observation is consistent with mutual exclusivity of variation. In this case, 
certain genes will sufficiently disrupt a pathway or process eliminating the need for any other 
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variants in this pathway or process. If this holds true, an exploration of the mutually exclusive 
pathways and processes will yield great new insights into the events that lead to leukemic 
transformation in infants. 
3.4 Discussion 
The data presented in this chapter corroborate and greatly extend the findings made in our 
KMT2A-R- cohort. They confirm that an enrichment of putatively deleterious variation in 
leukemia-associated genes is a common feature of IL patients. This enrichment has not been 
observed in any of the control populations that we have sequenced, or in other publicly available 
control cohorts. Importantly, this observation holds when we use the much more stringent 
ExAC-based filtering strategy that we have more recently employed.  The previous data had a 
number of false-positives in some of our focus genes. These even persisted when we performed 
Sanger sequencing on individual variants. The aggregation of thousands of individual exomes 
allows for the detection of artifact with great sensitivity. The fact that we eliminated a number of 
now known artifacts and still observed a marked enrichment of RNS variation in these leukemia-
associated genes is strong evidence that we are capturing biologically relevant phenomena. This 
enrichment was present in KMT2A-R+ IL. This provides more evidence that, while a powerful 
driver of leukemia, this rearrangement is insufficient to lead to a phenotype as severe as IL when 
acting in isolation.  Rather, rearrangements may need the presence of a strong predisposition 
towards leukemia in order to bring it about in utero. 
The notion that germline variation can strongly pre-dispose towards the development of cancer is 
becoming increasingly accepted133,134. Most studies, however, do not expand beyond known 
cancer pre-disposition genes.  We, too, used prior knowledge as a proof of concept in this study. 
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However, we were, at the time of writing, unique in our expansion to a genome-wide 
interrogation of cancer-predisposing germline variation. We were able to do this because of a 
much increased sample size, and strong controls both performed in house and publicly available. 
Our genome wide study provided several new candidate genes, each of which might play a role 
in infant leukemogenesis. These genes might act independently and contribute to susceptibility to 
IL.  Interestingly, though, many of the genes perform similar cellular functions.  Specifically, 
ubiquitin ligation, transcriptional modifiers and RNA binding proteins are quite common in this 
group.  This finding suggests that these processes might be particularly important in IL. It is also 
noteworthy that aside from KMT2B, KMT2C and PTEN, none of these genes have previously 
been implicated in either adult leukemia or a pan-cancer cohort18. There are probably several 
reasons for this.  First, IL is a unique clinical entity135,136, and, as such, should have unique 
genetic basis. Second, the fact that these genes are not frequently mutated in adult cancers 
supports the argument that the developmental context of genetic events might be as important as 
the events themselves. An insult that leads to cancer when it occurs early in development might 
be benign, or relatively so, in mature cell types and organisms. Finally, it is unlikely that a 
germline variant is equivalent to a somatic mutation. The subtle changes in activity or gene 
dosage that result from germline variation, but are present though the entirety of an individual’s 
development and life, will likely have a different effect than the sudden loss or change in a gene 
much later in life as a result of somatic mutation.  
Regardless of the explanation for this observation, it has implications for the management and 
treatment of IL. Currently, outcomes for these patients are poor. Early treatment regimens were 
insufficient and saw frequent relapse, but attempts to intensify treatments resulted in significant 
treatment-related morbidity and mortality137,138. Similarly, stem cell transplant is of limited 
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benefit for these patients28. The genes that we have shown to be highly variant in IL will provide 
insights into the molecular basis of IL.  Since these genes were not seen in adult cancers, they 
might represent unique targets that will benefit IL patients where adult and childhood based 
treatment regimens have largely proved ineffectual. Further, taking into account the 
developmental timing and the differences between germline and somatic genetic insults will 
allow for a better informed therapeutic strategy.  
In addition to informing our understanding of IL and potential treatments, this list of highly 
variant genes provides insights into the pathways and cellular functions that are critical for 
normal hematopoietic development. It seems that most of the genes work in some way to 
modulate or enforce a transcriptional program. This is clearly central to cellular function and 
behavior.  It is likely that many of these genes, then, will be critical in several cell types. Still, the 
fact that they are observed to have such an increase in deleterious variation in IL specifically, 
suggests that they might be particularly important in the context developmental hematopoiesis. 
This system requires balance between self-renewal and differentiation139, and perturbations 
during its establishment might be particularly damaging. Future studies into the specific 
functions of these genes in a hematopoietic context should be performed and will likely inform 
both development and IL alike. 
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Figure 3.1: Frequency of Rare Alleles in ExAC and EVS. The number of RNS alleles present 
in a given gene divided by the number of alleles sequenced in the cohort is plotted.  It is evident 
from the plot that, despite very different sample sizes, this measure of variation is very similar 
between different cohorts, suggesting that the rates of genetic variation in a given gene are 
conserved. 
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Figure 3.2: Frequency of Rare Alleles in ExAC and NHS. The same measure as Figure 3.1, 
but with samples from the NHS cohort replacing the EVS server on the y-axis. The linear 
relationship is still largely preserved, but, due to the much smaller sample size, there are a 
number of random fluctuations. To mitigate the influence of these random outliers, we applied a 
LoF intolerance test. Genes that are tolerant of LoF mutation are in gray; those that are not 
remain in black. KMT2B and KMT2C are depicted in red. 
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Figure 3.3: Frequency of Rare Alleles in ExAC and IL. The same measure as Figures 3.1 and 
3.2, and colored as in 3.2.  There is still a number of randomly “enriched” genes as an artifact of 
small sample size.  However, relative to the NHS controls there are many more intolerant of LoF 
mutation.  The solid gray line is a linear model fit to the data and the dotted gray lines are 5 
standard deviations outside of this line. 
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Figure 3.4: Frequency of RNS variants in KMT2 genes and COMPASS complexes. The 
number of RNS variants per individual is plotted for each of the KMT2 family genes along with 
the same measure for genes that are either shared between both COMPASS complexes or unique 
to the KMT2A/B complex of the KMT2C/D complex.  Complex members are defined here132 
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Figure 3.5: Location of variants in KMT2 genes in IL cases and controls. Lollipop plots for 
KMT2A (MLL1), KMT2B (MLL2), KMT2C (MLL3) and KMT2D (MLL4). While there does 
not seem to be variant hotspots, there is a clear difference in the number and types of variants 
present in the IL cases relative to controls. 
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Figure 3.6: Co-occuring variants by gene and patient. The variants present in each patient in 
each of the top variable genes was plotted.  
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Table 3.1: Enrichment of RNS Variants in Leukemia-associated Genes. 
Leukemia Subtype KMT2A-R status ALL Enrichment p-value AML Enrichment p-value 
ALL + 0.001 - 
ALL - 0.002 - 
AML + - 1.25e-10 
AML - - 4.67e-14 
Control - NS NS 
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Table 3.2: Genes with significantly more RNS variation in IL compared to ExAC. This list 
was further filtered by LoF intolerance and the control NHS sample. 
KMT2C  MYCBP2 CIC 
KMT2B DYNC1H1 UBR5  
PTEN CEP350 HECTD1 
CHD5 CNOT1 USP34 
CHD8 HUWE1 BIRC6 
LRP1B  ACIN1 UBR4 
ZMYM3 ARID1B  
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4. Modeling Hematopoietic Development in 
vitro 
4.1 Introduction 
The data from our germline exome sequencing yielded some important insights into the biology 
of IL. The notion that germline variants play a role in the development of IL, which was not 
widely anticipated, seems quite evident in our data. This finding and the in utero onset of IL 
suggest that this disease is, at least partially, the result of a defect in the establishment of a 
normal hematopoietic system. While it is not feasible to test this directly in patients, the list of 
genes that are more highly variant in IL patients provides several potential candidates for in vitro 
modeling.  The evidence that each of them might have a role in infant leukemogenesis is strong, 
however, we focused on KMT2C as an initial proof of concept for several reasons. The role of 
KMT2A rearrangements in IL is clear22,31,35,140,141. The family members KMT2B and KMT2C 
are significantly mutated in a pan-cancer dataset131. KMT2C is also present in our original list of 
leukemia associated genes. Finally, after our analysis of the KMT2A-R- IL patients, KMT2C 
appeared to have compound heterozygous variants in every case of infant AML and most cases 
of infant ALL. Our subsequent analysis tempered this finding, but the focus on KMT2C is still 
supported in these later data as well. 
To appropriately model developmental hematopoiesis, and how it might go awry in the 
development of IL, we turn to an hPSC-based directed differentiation system142.  There are 
numerous advantages to using this system. The cells are human and thus should accurately 
reflect the role of human genes. Much of hematopoiesis is conserved in vertebrates, but the role 
of certain genes is not always consistent across species143. The timeframe for these experiments 
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is shorter than that required to perform animal studies. The two programs of hematopoiesis that 
occur during embryonic development can be separated and explored individually144.  A quick 
and robust method to introduce transgenes that are expressed throughout the differentiation 
process has already been developed145. Finally, a great deal of work has already been done to 
establish and characterize a number of time points throughout the differentiation process, 
allowing for the rapid and relatively easy interrogation of a number of developmental stages 
along the hematopoietic axis56,93,144. 
4.2 Materials and Methods 
4.2.1 iPSC lines 
The control line (IC1) used in this study was generated from fibroblasts taken from a healthy 
adult male. They were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit 
from Invitrogen (Cat. #A16517) according to the manufacturer’s instructions.  Briefly, this kit 
uses a non-inserting Sendai Virus expressing the four reprogramming factors, OCT4, SOX2, 
KLF4 and MYC (OSKM). 
4.2.2 CRISPR knockout of KMT2C 
Guide RNAs targeting exon 3 of KMT2C were generated and checked for off-target effects.  IC1 
cells were transfected with Cas9 and the validated guide RNAs.  The resulting cleavage sites 
were rejoined by non-homologous end joining, resulting the expected deletion events.  Screening 
revealed that several knock out clones were generated (Figure 4.1). The clone used in this work 
is dubbed IC1_MLL3KO 
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4.2.3 hPSC growth and maintenance 
The day before hPSCs are to be split or thawed, seed an appropriate number wells with irradiated 
MEFs.  Aspirate the media from each well to be split.  Add 1 mL room-temperature trypsin-
EDTA to each well.  Incubate at room temperature for 1 minute. Aspirate the trypsin and stop the 
reaction by adding 1 mL stop media per well.  Gently scrape the cells until they have all lifted off 
the plate. Add 1 mL wash media to each well, and triturate 3-5 times with a 2 mL serological 
pipette.  This should result in relatively uniform clusters of 5-15 cells.  Harvest each well and 
centrifuge at 1200 rpm for 5 minutes. Resuspend the cells in 2 mL hESC media per well to be 
seeded and aliquot the cells onto MEFs.  Typically, the cells will be passaged at a 1:12 split 
every 5 days. 
4.2.4 Differentiation Protocol 
Day 0: Generation of Embryoid Bodies (EBs) 
The day before EB generation, cells are split and plated onto matrigel-coated dishes to deplete 
the MEFs.  The MEF-depleted cells are treated with 1 mL of a 1:4 solution of Trypsin-
EDTA:PBS for 30s. The trypsin is removed and the reaction is stopped by the addition of 1 mL 
stop media per well.  The scrape each well with a cell-scraper until all cells have lifted from the 
plate. Add 1 mL of wash media to each well and triturate with a 2 mL serological pipette until 
the cells have formed clusters of 10-20 cells. Collect each well into a 50 mL conical tube and 
centrifuge at 800 rpm for 5 minutes. Aspirate the supernatant and centrifuge for an additional 5 
minutes.  Resuspend the cells in 2 mL of Day 0 media for every 2 wells of cells harvested and 
distribute into polyheme-coated 6-well plates. Incubate at 37C 5% O2. 
Day 1: Feeding EBs 
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Add 2 mL of Day 0 media supplemented with 10ng/mL bFGF to each well of the culture 
Day 2: Induction 1 
This step should be performed 42 hours after EB generation. Harvest up to 12 wells of culture 
into one 50 mL conical and centrifuge at 400 rpm for 5 minutes.  Aspirate the supernatant and 
resuspend in pure IMDM.  Spin another 5 minutes at 400 rpm.  This step will remove much of 
the debris that is present in the cultures at this point.  After the second centrifugation, aspirate the 
supernatant and resuspend 2 mL in Day 2 media for each well of culture harvested. Return the 
aggregates to the original polyheme-coated plates. Incubate at 37C 5% O2. 
Day 3: Dissociation for Mesoderm Analysis or Induction 2 
If a mesoderm analysis will be performed, harvest the cells into a 50 mL conical and centrifuge 
at 1200 rpm for 5 minutes.  Resuspend in 3 mL trypsin-edta. Incubate in a 37C water bath for 5 
minutes.  Add 3 mL of stop media and centrifuge at 1200 rpm for 5 minutes. Resuspend the cells 
in IMDM supplemented with 2% FCS and pass through a filter to ensure a single cell 
suspension. This suspension is ready for downstream analysis. 
If no mesoderm analysis will be performed, harvest the cells into a 50 mL conical and centrifuge 
at 1200 rpm for 5 minutes.  Wash once in IMDM and centrifuge again.  Prepare 2 mL of Day 3 
media for each well of culture.  Resuspend the washed aggregates in Day 3 media and return to 
the same polyheme coated plates. Incubate at 37C, 5% O2. 
Day 6: Feeding EBs and supplementing cytokines 
Prepare 2 mL of Day 6 media per well of culture and add it to each well. 
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Day 8+: Dissociation 
Harvest up to 12 wells of culture into a single 50 mL conical.  Centrifuge at 1200 rpm for 5 
minutes.  Aspirate the supernatant and resuspend the cells in 3-6 mL trypsin-edta. Incubate for 8 
minutes in a 37C water bath. Stop the reaction by adding 3-6 mL stop media and centrifuge at 
1200 rpm for 5 minutes.  Aspirate the supernatant and resuspend in 3-6 mL Collagenase Type II. 
Incubate in a 37C water bath for 30-60 minutes.  Add 3-6 mL stop media and centrifuge at 1200 
rpm for 5 minutes.  Aspirate the supernatant and resuspend the cells in IMDM supplemented 
with 2% FCS.  Pass the cells through a filter to ensure a single cell suspension.  The cells are 
ready for downstream assays and/or analysis. 
4.2.5 Flow Cytometry and antibodies 
Table  contains a list of the antibodies, fluorophores and concentrations used for each 
experiment.  
Once the cells are in a single cell suspension, wash them 5 times (day 3) or 2 times (all other 
days) in IMDM+2%FCS. Resuspend the cells at a concentration of up to 1 x 10^6 cells/100 uL. 
Add the appropriate antibodies and incubate on ice for 30 minutes.  Add 1 mL IMDM+2% FCS 
and centrifuge at 1200 rpm for 5 minutes.  Aspirate the supernatant and resuspend the cells at a 
concentration of 5x10^6 cells/mL. 
4.2.6 Endothelial to Hematopoietic Transition (EHT) Assay 
Resuspend CD34+, CD43- endothelial cells, or CD34+, CD43-, CD73-, CD184- hemogenic 
endothelial cells in Day 8 media at a concentration of 300,000 cells/mL. Add 30 uL of cell 
suspension per well of a matrigel-coated 24-well plate and incubate overnight at 37C 5% O2. 
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The next day, add 1 mL Day 8 media to each well.  The cells will undergo EHT over the next 
several days.  They can be harvested at Day 8+8 for definitive (CHIR99021-conditioned) 
cultures or at Day 9+8 for primitive (IWP2-conditioned) cultures. 
4.2.7 Serial Replating Assay 
Harvest cells that have undergone EHT and centrifuge them at 1200 rpm for 5 minutes.  Aspirate 
the supernatant and resuspend them in 1 mL Day 8 media.  Count the cells with a hemocytometer 
and add enough Day 8 media to arrive at a concentration of 250,000 cells/mL.  Add 1 mL of cell 
suspension to each well of a non-adherent 24 well plate.  Repeat this process every 7 days until 
the cultures have either failed or demonstrated serial replating capacity. 
4.2.8 Methylcellulose-based Colony Forming Assay 
Add 50,000 cells from a single cell suspension to a 2.5 mL aliquot of MethoCult (StemCell 
Technologies cat. #04034).  Vortex thoroughly.  After the mixture has settled and the air bubbles 
have largely disappeared, draw up 1 mL of Methocult into a syringe and aliquot into a 35-mm 
dish.  Repeat for the remainder of the Methocult and cell mixture.  Place all 35-mm dishes into a 
150-mm with a single uncovered 35-mm dish filled with water. Place the larger dish into the 37C 
incubator.  Colonies are counted 7-9 days after plating. 
4.2.8 T-cell Assays 
Resuspend cells in T-cell Media and plate onto OP9-DL4 stroma.  Passage the cells every 4 days, 
splitting them 1:5.  After 17-21 days in culture, proceed with flow cytometry. 
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4.2.9 StemPro 
Thaw StemPro34 supplement overnight at 4C. Add supplement to 500 mL StemPro34 Medium.  
Add 5 mL Penn/Strep. Mix by gently inverting. Incubate at 37C for 30 min. Aliquot and store at 
4C. 
4.2.10 AAVS Targeted MLL-AF9 Construct 
The sequence of a common MLL-AF9 fusion was obtained from the NCBI.  This construct was 
synthesized and cloned into the TRE AAVS plasmid by Genewiz. 
4.2.11 AAVS Transfection 
Treat a 5-day old culture of hPSCs with trypsin until they are a single cell suspension.  Count the 
cells and seed 250K/well of drug-resistant MEFs.  Include ROCK inhibitor in the hPSC medium. 
The next day, change the medium to P/S-free hPSC medium with no ROCK inhibitor. Mix 1.2 
ug neo-rtTA plasmid, 1.2 ug TRE-MA9 and 0.3 ug of each ZFN plasmid in 100 uL of P/S-free 
IMDM. Add 9 uL XtremeGENE 9 and incubate 25 minutes at room temperature.  Slowly add 
100 mL DNA mixture to each well. The next morning, feed with P/S-free hPSC medium.   Add 
2.5 ug/mL puromycin and incubate 2.5 days.  Return the cells to P/S-free medium for 1 day.  
Incubate for the remaining days of selection in medium containing 20 ug/mL G418. Manually 
pick Individual clones that have grown out for genotyping. 
4.2.12 AAVS Screening 
For the successful generation of a dox-inducible cell line, both wildtype alleles must be lost, and 
one each of the rtTA and the TRE plasmids must be in their place.  Thus, 3 PCR reactions are 
performed. First, to check for wildtype allele loss, second for the rtTA integration and third for 
the TRE integration. The primers used are: 
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AAVS WT HET F: CCC CTA TGT CCA CTT CAG GA     
AAVS WT HET R: CAG CTC AGG TTC TGG GAG AG 
CAG AAV scrn FWD: TCCTGGGCAAACAGCATAA 
TRE AAV scrn REV: GAAGGATGCAGGACGAGAAA 
TRE AAV scrn FWD: GCAATAGCATCACAAATTTCAC 
TRE AAV scrn REV: GAAGGATGCAGGACGAGAAA 
4.3 Results 
As there is known heterogeneity in the behavior of different pluripotent cell lines, we first sought 
to establish the baseline differentiation characteristics in IC1, our control cell line derived from a 
healthy adult male. To start, we used the same differentiation schedule and media formulations 
as has been previously reported142 (Figure 4.2). As expected, IC1 cells differentiated for 3 days 
in the presence of BMP4 and bFGF acquired a KDR+ mesoderm phenotype (Figure 4.3).  This 
mesoderm expressed either high or low-absent levels of CD235a when treated with the small 
molecules IWP2 or CHIR90221 respectively.  These markers are indicative of mesoderm that is 
primed to undergo either primitive or definitive hematopoiesis.  We continued these cultures, 
changing the media and adding appropriate cytokines until day 8 of differentiation.  Again, this 
line exhibited the expected phenotypes. Specifically, cells that were treated with IWP2 had a 
CD34+, CD43- population that was slowly maturing into a CD34-, CD43+ population with a 
gradient of cells at various points in this transition, indicative of active and ongoing primitive 
hematopoiesis (Figure 4.4).  To further show establish the efficacy of primitive hematopoiesis, 
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we performed a colony forming assay and observed robust, multi-lineage colony forming 
potential (Figure 4.5).  By contrast, the cells that were treated with CHIR90221, and were thus 
primed exclusively for definitive hematopoiesis, had only a CD34+, CD43- population. This 
population requires additional signaling to undergo hematopoiesis, so to further characterize the 
behavior of this line, we sorted these mixed endothelial cells and used them as inputs for both an 
endothelial-to-hematopoietic transition (EHT) assay, and a T-cell assay.  
In the EHT assay, sorted CD34+,CD43- cells were plated onto matrigel coated plates and 
allowed to adhere in low volume overnight. Cytokine rich medium was added the next day and 
the cells were observed for 8 days. Over this time, the cells first divide and expand to form an 
endothelial-like monolayer of adherent, close packed cells. Various cells begin to become more 
round and protrude up from their surrounding endothelium. Eventually, these cells will release 
completely to enter suspension and take on a round, small, bright phenotype consistent with a 
hematopoietic cell.  Figure 4.6 shows a series of micrographs detailing this process. After 8 days, 
the hematopoietic cells can be re-plated and followed over several weeks.  Initially, the culture is 
predominantly comprised of hematopoietic progenitors that have the ability to divide several 
times, and differentiate into a variety of mature hematopoietic cell types. Over time, these cells 
become terminally differentiated and lose the ability to self-renew. As a result, the number cells 
in culture initially expands, but eventually contracts as the cells senesce and die (Figure 4.7). 
The T-cell assay takes the same cell population as input.  The cells are plated onto a layer of 
OP9-DL4 stroma that provides high levels of Notch signaling requisite for T-cell maturation. 
They are passaged regularly over 21 days and then interrogated by flow cytometry.  As expected, 
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the differentiated IC1 cells were able to differentiate into T-cells as evidenced by the expression 
of both CD4 and CD8 (Figure 4.8). 
Together, these experiments establish that IC1 cells behave as expected in this differentiation 
protocol.  They give rise to both primitive and definitive hematopoietic cells that form colonies 
and persist in culture for an expected timeframe. 
We next turned our attention to the KMT2C KO line that we derived from our IC1 cells. We 
again sought to establish the ability of these KMT2C KO cells to undergo hematopoietic 
differentiation and determine if any differences existed between the IC1 and KMT2C KO cell 
lines during the differentiation process. We proceeded as before, first examining the cultures 
after 3 days. As shown in Figure 4.9, the cells had taken on the expected mesodermal phenotype, 
with appropriate responses to induction in the presence of either Wnt stimulation or block. 
Similarly, after 8 days in culture, the cells had acquired the anticipated endothelial phenotype 
(Figure 4.10). However, when we performed a colony forming assay on primitive cells we 
observed a marked decrease in the number of colonies that arose (Figure 4.5).  More strikingly, 
when we performed EHT and T-cell assays, we observed a complete lack of definitive 
hematopoiesis (Figures 4.8 and 4.11).  
To further explore this result, we repeated the differentiation, this time adding CD73 and CD184 
antibodies to the flow panel on day 8.  CD73 and CD184 enable the identification of the different 
types of endothelium present in the CD34+ CD43- definitive cells56.  When we added these 
markers, the reason for the KMT2C KO cell line’s failure to undergo EHT and make T-cells was 
readily apparent. The endothelial cells that have hematopoietic potential, hemogenic endothelium 
(HE), are CD73- CD184-, this population is present in the IC1 cultures but effectively absent in 
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the KMT2C KO cultures (Figure 4.12). To ensure that the lack of HE as defined cytometrically, 
we sorted all endothelial cells (i.e. CD34+,,CD43-) from both IC1 and KMT2C KO cultures, and 
performed an EHT assay.  As before, only the IC1 cultures gave rise to any meaningful amount 
of cells in suspension.  Still, we collected all of the cells from each line after 8 days of EHT and 
performed a colony forming assay. The IC1 line gave rise to multiple robust colonies, while the 
KMT2C KO produced effectively none (Figure 4.13). A similar, though less severe, phenotype 
was seen in primitive differentiations as well (Figure 4.5).  This indicates that KMT2C is 
required for efficient establishment of hematopoiesis in this in vitro model. 
4.4 Discussion 
hPSC cells that lack KMT2C are impaired in their ability to undergo primitive hematopoietic 
differentiation in our system. Similarly, KMT2C knockout cells fail to specify definitive HE in 
this same system. The observation of this striking phenotype validates our bioinformatic analysis 
of IL exomes.  We found that this gene much more highly variable in IL patients than population 
controls. We postulated that these variants resulted in impaired function of KMT2C and thereby 
led to aberrant hematopoietic development. In our hPSC based model of hematopoietic 
development, we see marked dysfunction in the absence of KMT2C. It will be interesting to see 
if other genes that were flagged in our analysis will have similarly strong phenotypes in this or 
other systems.   
While this study works well as a proof of concept, there are several caveats and open questions. 
First, the complete lack of definitive HE and impaired primitive hematopoiesis do not 
immediately suggest leukemia. There are several possible explanations for this.  First, we have 
introduced only one genetic lesion when our bioinformatics analysis, as well as years of cancer 
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genomics, suggest that dysfunction in several genes is required for frank tumorigenesis17. Also, 
the infants in our sequencing studies generally have heterozygous non-synonymous point 
mutations in KMT2C, whereas our cell line has a complete knockout of the gene. Thus, our cells 
should have a complete lack of KMT2C function, but the IL patients are much more likely to 
have a hypomorphic allele. This difference might result in a less severe phenotype than the one 
we observed. Either way, a block in differentiation is consistent with cancer development146–148, 
especially when combined with a proliferative insult from KMT2A rearrangements or RAS 
mutations that are relatively common in IL22,149. 
KMT2C disruption led to dysfunction in both the primitive and definitive hematopoietic 
programs. This emphasizes the importance of this gene in these contexts. However, this finding 
does not provide any insight into the cell-of-origin in IL. Since both programs were affected in 
the absence of this gene, the possibility still remains that either program could be the one that is 
hijacked in infant leukemogenesis. The possibility that aberrant primitive hematopoiesis might 
be transformed into leukemia is compelling. Given the clinical and phenotypic differences 
between IL, later childhood leukemia, and even other KMT2A-R+ leukemia later in life, a 
primitive cell-of-origin in the former is quite possible141,150. Our results are consistent with this 
possibility, but are far from confirming it. However, several groups have shown that hPSCs 
derived from AML patients re-acquire leukemic properties when differentiated into 
hematopoietic cells151,152. Interestingly, the differentiation protocols used in these studies are 
likely to form a mixture of primitive and definitive cells. In this case, the primitive program, 
which is highly proliferative early on, is likely to represent a majority of the cells in these 
cultures. Thus, the cells that are able to serially re-plate and establish leukemia in transplanted 
mice, are very possibly derived from the primitive program. Establishing whether this is the case 
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is an important goal, and is actively being explored. This knowledge will definitely inform 
developmental biology and the etiology of IL. It could also lead to much needed improvements 
in IL treatment. 
Pluripotent cells derived from patients with various hematopoietic disorders have stereotypic 
lesions that are presumably the drivers that lead to the re-acquisition of leukemic phenotypes 
when these cells are differentiated back into hematopoietic lineages151,152. These studies 
demonstrate that leukemia can be modeled by in vitro hPSC differentiation strategies. However, 
these cells start from cells that have already transformed into frank leukemia. Our attempts to 
model IL work in the opposite direction; starting from phenotypically normal cells, and adding 
genetic insults until transformation is achieved.  The deletion of KMT2C was not able to 
recapitulate IL in our differentiation, but this single insult was expected to be insufficient for a 
complete leukemic transformation. With the addition of other insults, we anticipate that we too 
will be able to achieve a leukemia-like phenotype from our cells. This model will be more 
relevant to IL because it will be based on sequencing studies in IL, and will be able to distinguish 
the cell-of-origin relevant to IL. Further, we will have a closed system in which the genetic 
insults will all be known, and the cell line in which the insults were introduced is epigenetically 
normal as evidenced by its ability to undergo hematopoietic differentiation normally. 
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Figure 4.1: Schema of KMT2C KO generation. The CRISPR cut sites are shown and the 
various alleles that resulted from the non-homologous end joining are shown. Each introduces a 
frameshift mutation very early in the protein. 
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Figure 4.2: Differentiation schema.  A cartoon depiction of the differentiation process that we 
used. Cells that are conditioned with CHIR09221 and become definitive, are in blue, while those 
in yellow were treated with IWP2 and will have a primitive phenotype. 
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Figure 4.3: Day 3 flow cytometry in control cells. Panel A depicts a CHIR09221-treated 
culture. The lack of CD235a cells indicates that there is no primitive specified mesoderm 
present. Conversely, the culture shown in Panel B was treated with IWP2 to specify primitive 
primed mesoderm. 
a) 
 
b) 
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Figure 4.4: Day 8 flow cytometry in control cells. As in Figure 4.3, the control cells that were 
treated with the two modulators of Wnt-signaling have the expected phenotypes in flow 
cytometric assays. The CD43 expressing cells present in the IWP2 treated culture are indicative 
of active primitive hematopoiesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
Figure 4.5: Colony-forming assays in primitive-specified cells. The average number of 
myeloid and erythroid colonies per 10,000 cells is depicted. There is a significant decrease in 
both lineages in KMT2C (MLL3) KO cells. 
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Figure 4.6: Micrographs of EHT in control cells. The EHT process occurs over several days 
and is documented below.  The cells initially have an endothelial phenotype, and fill in to create 
a continuous monolayer.  Over time, certain cells will become rounder and eventually non-
adherent to release into the medium. 
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Figure 4.7: Expansion of serially passaged control cells. The cells that undergo EHT are a mix 
of progenitors and more mature cells.  As a group they are capable of expanding over several 
days.  However, HSCs are not supported in this assay, so eventually the ability to expand is 
exhausted and the culture collapses. 
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Figure 4.8: T-cell assay in control and KMT2C KO cells. Control (IC1) cells have robust T-
cell potential indicating successful definitive hematopoiesis.  KMT2C (MLL3) KO cells, 
conversely, repeatedly failed to generate T-cells. 
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Figure 4.9: Day 3 flow cytometry in KMT2C KO cells. At day 3 the KMT2C cells displayed 
the expected phenotypes and were indistinguishable from the control line using this measure at 
this time point. 
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Figure 4.10: Day 8 flow cytometry in KMT2C KO cells. By flow cytometry, the day 8 
KMT2C KO cultures displayed the expected cell surface markers. The populations were 
comparable in size to the same populations in control cells for a given assay. 
a) 
 
b) 
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Figure 4.11: KMT2C (MLL3) KO cells fail to undergo EHT. Despite having a CD34+,CD43- 
endothelial population that was similar to that of control cells, the KMT2C KO cells did not 
undergo EHT.  These cultures were watched for several more days to see if there was simply a 
timing difference between the two lines, but even after weeks in culture there was no indication 
of EHT in KMT2C KO cells.  
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Figure 4.12: Day 8 flow cytometry in control and KMT2C KO cells. The addition of two 
markers allowing differentiation of various types of endothelium clearly demonstrates that the 
HE (red box) is not present in the KMT2C KO cells, despite similar amount of arterial 
endothelium (purple box) in both cultures. 
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Figure 4.13: Definitive colony-forming assays. Definitive-specified KMT2C KO cells do not 
form colonies, indicating that the few cells that are present in the HE gates lack any hemogenic 
potential. 
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Table 4.1 Day 0 Medium 
Component Concentration 
SFD -- 
Glutamine 1% 
Transferrin 150 ug/mL 
Ascorbic Acid 50 ng/mL 
MTG 11.25 ug/mL 
BMP4 10 ng/mL 
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Table 4.2 Day 2 Medium 
Component Concentration 
SFD -- 
Glutamine 1% 
Transferrin 150 ug/mL 
Ascorbic Acid 50 ng/mL 
MTG 11.25 ug/mL 
BMP4 10 ng/mL 
Activin A 0.3 ng/mL 
bFGF 5 ng/mL 
CHIR09921/IWP2 3 uM 
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Table 4.3 Day 3 Medium 
Component Concentration 
StemPro34 -- 
Glutamine 1% 
Transferrin 150 ug/mL 
Ascorbic Acid 50 ng/mL 
MTG 11.25 ug/mL 
VEGF 15 ng/mL 
bFGF 5 ng/mL 
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Table 4.4 Day 6 Medium 
Component Concentration 
StemPro34 -- 
Glutamine 1% 
Transferrin 150 ug/mL 
Ascorbic Acid 50 ng/mL 
MTG 11.25 ug/mL 
VEGF 15 ng/mL 
bFGF 5 ng/mL 
IL6 10 ng/mL 
SCF 50 ng/mL 
IL11 5 ng/mL 
EPO 2 U/mL 
IGF1 25 ng/mL 
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 Table 4.5 Day 8+ Medium 
Component Concentration 
StemPro34 -- 
Glutamine 1% 
Transferrin 150 ug/mL 
Ascorbic Acid 50 ng/mL 
MTG 11.25 ug/mL 
TPO 30 ug/mL 
IL3 30 ug/mL 
SCF 100 ug/mL 
EPO 4 U/mL 
FLT3L 10 ug/mL 
IGF1 25 ng/mL 
IL6 5 ug/mL 
IL11 5 ug/mL 
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Table 4.6 Serum Free Differentiation (SFD) Medium 
Component Amount 
IMDM 750 mL 
Ham’s F12 250 mL 
10% BSA – Fraction V  5 mL 
B27 Supplement 10 mL 
N2 Supplement 5 mL 
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Table 4.7 Antibodies 
Target Fluorphore Conentration 
CD34 APC 1:100 
CD43 FITC 15:100 
CD73 PE 2:100 
CD184 BV421 2:100 
CD235a APC 1:100 
KDR Biotin (PE-SA) 15:100 (1:100) 
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5. Transcriptional and Epigenetic Profiling of 
hPSCs and Differentiating Hematopoietic 
Cells 
5.1 Introduction 
KMT2C deficient cells have a marked impairment in primitive and definitive hematopoietic 
differentiation. This differentiation process starts from an hPSC, continues through a 
mesodermal intermediate, an endothelial intermediate and culminates in hematopoietic 
progenitors and mature hematopoietic cells84,93,144,153. At each of these steps there is a cell-type 
specific transcriptional and epigenetic program. These programs determine the cell’s identity, 
future potential and responsiveness to intrinsic and extrinsic stimuli. As the differentiation 
process progresses, various genes will need to be up- or down- regulated in a specific order and 
at specific times. This transcriptional control is effected by transcription factors and epigenetic 
modifiers, which will make genes more or less accessible by modifying chromatin accessibility, 
promoter and enhancer activation and possibly other factors. 
KMT2C is, among other functions, a histone monomethylase with specificity for lysine 4 on 
histone 3. This mark (H3K4me1) is associated with active enhancers and areas of open 
chromatin. The enhancers regions targeted by KMT2C will have a positive impact on 
transcription and upregulate target genes.  KMT2C has been incompletely characterized, 
however, and has several other domains that likely impart other functions to this very large 
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protein. Indeed, there is some evidence that KMT2C is capable of binding DNA directly, acting 
as a ubiquitin ligase, and responding to retinoic acid signaling in addition to methyltransferase 
activities. This wide range of potential activities explains the severe phenotype that we observed 
as well as the other phenotypes that have been associated with KMT2C dysfunction. 
Recognizing that KMT2C would likely influence a number of transcriptional factors and 
epigenetic features during hematopoietic differentiation, we interrogated a number of these, 
including transcript abundance via RNA-seq, chromatin accessibility via ATAC-seq, and H3K4 
monomethylation via ChIPmentation. We performed these at various timepoint throughout the 
differentiation process because the effect of KMT2C deletion might act at each independently or 
progressively as the process moves forward. 
5.2 Methods 
5.2.1 Cell sorting and Isolation 
Cells were dissociated and stained as previously described (Section 4.2). Sorting was performed 
on a BD Aria FACS machine.  For day 3 mesoderm samples, cells that were KDR+ and 
CD235a- were kept.  For RNA-seq all of the cells that matched the phenotype of interest were 
kept, yields ranged from 3x10^5 – 1.5x10^6.  For ATAC-seq and ChIPmentation, cells were split 
into 50,000 cell aliquots before processing. 
5.2.2 RNA isolation 
Sorted cells were washed and resuspended in 1 mL TRIzol reagent and frozen at -80C until 
processed.  When all the samples had been collected, the -80C TRIzol samples were thawed at 
room temperature.  200 uL chloroform were added to each sample which was then mixed and 
88 
 
incubated at room temperature for 5 minutes.  Samples were centrifuged for 15 minutes at 
12000g, 4C.  The upper aqueous phase was transferred to a fresh 1.5 mL tube, and 500 uL 
isopropanol was added.  After a 10-minute incubation at room temperature, samples were 
centrifuged at 12000g for 10 minutes at 4C.  The supernatant was discarded and the RNA pellet 
was washed once in 1 mL 70% ethanol followed by centrifugation at 7500g for 10 minutes at 4C.  
The supernatant is discarded and the pellet is allowed to dry for 5-10 minutes at room 
temperature. The RNA is then resuspended in ddH2O.  RNA yield and quality was determined 
by nanodrop. 
5.2.3 RNA-seq prep 
Total RNA was processed by first depleting ribosomal RNA using the Ribo-Zero kit (Illumina 
Cat. MRZH116).  This step removes the 28S, 18S, 5.8S, and 5S rRNA from solution, leaving a 
vastly enriched pool of mRNA.  The mRNA is reverse transcribed into cDNA using the Sigma 
Seqplex kit (Sigma Cat. No SEQR-10RXN).  Library preparation follows cDNA preparation and 
the samples are then sequenced on the Illumina HiSeq 3000 sequencer. 
5.2.4 RNA-seq analysis 
Raw reads were pseudo-aligned using kallisto154  and then differential gene expression analysis 
and transcript quantification was performed using sleuth155.  Other analysis was performed in R 
(Version 3.2.1, available at www.cran.r-project.org). 
 Reads were also aligned for using STAR156,157.  The .sam output from STAR was processed 
(sorted, indexed, converted to .bam) using samtools. The .bam files were visualized in the IGV 
genome viewer158. 
89 
 
5.2.5 ATAC-seq library preparation 
Sorted cells were washed then incubated for 5 minutes in lysis buffer. The lysed nuclei were then 
centrifuged at 500g for 15 minutes at 4C. After discarding the supernatant, the cells were 
resuspended in Transposase Buffer with 2 uL Transposase enzyme.  After 1 hour incubation at 
37C, the reaction was placed on ice, and cleaned up with a Qiagen MinElute kit. Amplify the 
DNA and add the necessary adapters and barcode with nine cycles of PCR. Following PCR 
perform SPRI AMPure bead clean up to enrich for <= 600 bp products.  Perform nine more PCR 
cycles to amplify the products further, and then follow with another AMPure clean up. The 
library can now be sequenced.  A minimum of 30 million reads should be obtained for each 
sample. 
5.2.6 ATAC-seq analysis 
Raw reads were aligned to hg19 using bowtie2, option –X 2000.  The resulting alignments were 
sorted, indexed, filtered and converted to .bam format using samtools. The filtering step removed 
reads mapping to blacklisted regions159, the mitochondrial genome and sex chromosomes. 
Picard-tools (http://broadinstitute.github.io/picard) removeDuplicates was used to eliminate PCR 
duplicates. Homer was then used to create tag directories.  Peaks were called using MACS 2160 
and annotated with Homer161.  ATAC-seq peak visualization was performed with IGV and 
subsequent analysis was performed in the R software package. 
5.2.7 ChIPmentation 
A detailed version of this protocol is available162. Wash cells once in PBS and fix in 1% 
paraformaldehyde for 10 minutes at room temperature.  Stop the reaction by adding glycine. 
Centrifuge 5 minutes at 500 x g at 4C to collect the cells.  Wash twice with ice-cold PBS, then 
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resuspend in RIPA buffer and incubate 10 minutes on ice. To isolate the nuclei, centrifuge 10 
minutes at 1000 x g, 4C. Samples were sonicated on a Covaris S220 to obtain fragment 200-700 
bp in length. Spin the samples at full speed for 5 minutes, 4C.  Increase the volume to 200 uL 
and incubate with H3K4me1 antibody (Diagenode  pAb-196-050) overnight at 4C. Concurrently, 
block Protein A coated magnetic beads overnight in in 0.1% BSA in PBS. Add blocked beads to 
the IP fragments and incubate 2 hours at 4C.  Wash beads in RIPA twice, RIPA-500 once and TE 
twice. Wash beads twice with cold Tris-HCl, then resuspend in 30 uL tagmentation reaction mix 
containing 1 uL Tagment DNA enzyme.  Incubate 10 minutes at 37C. Wash twice with RIPA 
buffer. Reverse crosslinking by incubating in 70 uL Elution Buffer for 1 hour at 55C then 8 
hours at 65C.  Transfer supernatant to a new tube.  Purify the DNA with SPRI AMPure beads 
(1:2 ratio). 
5.2.8 ChIPmentation analysis 
Raw reads were aligned to hg19 using bowtie2, option –X 2000.  The resulting alignments were 
sorted, indexed, filtered and converted to .bam format using samtools. The filtering step removed 
reads mapping to blacklisted regions159, the mitochondrial genome and sex chromosomes. 
Picard-tools (http://broadinstitute.github.io/picard) removeDuplicates was used to eliminate PCR 
duplicates. Homer161  was then used to create tag directories.  Peaks were called using MACS 
2160 and annotated with Homer.  ChIPmentation peak visualization was performed with IGV and 
subsequent analysis was performed in the R software package. 
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5.3 Results 
KMT2C KO cells have the most pronounced phenotype on day 8 in definitive-specified cultures, 
so we started our analysis here.  Since KMT2C KO cells do not generate any HE cells, we chose 
to characterize the CD34+, CD43- mixed endothelial population. We sorted this population 
(Figure 3.1) and performed RNA-seq, ATAC-seq and ChIPmentation for H3K4me1. Our initial 
analysis focused on the RNA-seq data. Differential expression analysis provided a number of 
transcripts that were significantly differentially expressed. We plotted the p-value from this 
analysis against the fold change in a given transcript to yield the volcano plot in Figure 5.2. 
Although we knew that KMT2C was a positive regulator of transcription we were surprised to 
find that the vast majority of transcripts that were upregulated and significantly differentially 
expressed were higher in the control cells. By contrast very few transcripts were upregulated in 
the KMT2C cells were upregulated. The few genes that were upregulated in KMT2C cells 
tended to be upregulated to a much lesser extent. This is consistent with the role of KMT2C, and 
suggests that the hematopoietic defects in KMT2C KO cells is a result of their inability to 
establish the relevant transcriptional profile for hematopoietic maturation. 
We further explored this data set by selecting the transcripts that exceeded a fold-change and 
significance based filter (Figure 5.2). The genes that met these criteria for either KMT2C KO 
cells or control cells were used as inputs into gene set enrichment software to determine the 
pathways or processes that were overrepresented in these data (Tables 5.1 and 5.2). As expected, 
the control cells were enriched in relevant pathways including Wnt signaling, notch signaling, 
specific HOX genes and BMP signaling (Figures 5.3,5.5-5.13). By contrast KMT2C KO cells 
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had upregulated transcripts important for neural development, heart development and SHH 
signaling (Figures 5.4-5.13).  The latter is interesting as SHH signaling is important for a number 
of developmental processes including hematopoiesis. Presumably however, the timing or amount 
of expression of these genes was inappropriate for normal hematopoietic development. 
The transcriptional identity of a cell is the result of several factors, including chromatin 
accessibility and enhancer activity.  We next analyzed our ChIPmentation and ATAC-seq data 
and found that they strongly supported our RNA-seq findings. The KMT2C competent cells had 
the expected tens of thousands of peaks at H3K4me1 sites.  In contrast to this, KMT2C KO cells 
had only a few thousand. Further, the read density around the control defined H3K4me1 peaks 
was much lower in the KMT2C KO cells (Figure 5.14). KMT2C is only one of several enzymes 
capable of placing H3K4me1 marks, so the peaks that remain in this dataset are presumably the 
result of other histone methyltrasnferases. 
We extended these observations by intersecting the ATAC-seq defined peaks with the H3K4me1 
peaks.  To do so, we extended the region around the H3K4me1 peaks by 500 bp on either side.  
In this expanded window, we looked for the presence of ATAC-seq peaks.  As expected, there a 
great deal of overlap between the H3K4me1 enhancer mark, and open chromatin (Table 5.3).  
The difference in definitive-specified control and KMT2C KO cells is pronounced at the day 8 
endothelial stage. We found that there is strong transcriptional and epigenetic support for this. 
However, it is entirely possible that the hematopoietic differentiation process was perturbed well 
before this stage.  To explore this possibility, we sorted day 3 KDR+, CD235a- definitive 
specified mesoderm cells from both control and KMT2C KO cultures (Figure 5.16), and 
performed RNA-seq. As before, we generated a volcano plot using fold-change and the p-value 
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of a test of differential expression (Figure 5.17). We applied a similar fold-change and p-value 
based filter to generate a list of significant transcripts for downstream analysis.  As before, there 
were more upregulated transcripts in the control cells than in the KMT2C knockout cells (Tables 
5.4 and 5.5). However, the difference at day 3 was much smaller than the difference at day 8.  
This suggests that the deficit in KMT2C takes time exert an effect. It also potentially explains 
why KMT2C KO cells are relatively similar to control cells at this time point based on flow 
cytometry. Still, despite the similarity in KDR and CD235a expression, an enrichment analysis 
shows that the transcriptional profiles of these two cell lines are quite different even at this time 
point. The control cells expressed a collection of genes responsible for expected processes 
including axis specification, cardiovascular differentiation, gastrulation and organismal 
patterning (Figures 5.18,5.20-5.27). In contrast, the KMT2C KO mesoderm expressed a 
seemingly disordered collection of transcripts involved in neural and heart development (Figs 
5.19-5.27). Further exploration of these observations is warranted, but as they stand, they are 
entirely consistent with our hypothesis of disordered gene expression and a failure to upregulate 
the relevant and necessary gene programs required for normal hematopoietic development. 
5.4 Discussion 
The two cell lines used in these studies differ only in their expression of KMT2C.  Thus any 
epigenetic biases that are present between various hPSC lines are not relevant in this context. 
Thus, the marked difference in the ability of KMT2C competent and KMT2C deficient cells to 
undergo hematopoietic differentiation is entirely the result of KMT2C dysfunction. In this study 
we observed that KMT2C KO cells do not upregulate a large number of genes that are 
upregulated in control cells.  These genes are enriched for important hematopoietic 
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differentiation pathways. The KMT2C KO cells do upregulate a smaller set of genetic programs 
that are unrelated to hematopoietic differentiation.  This is consistent with the idea that these 
cells are unable to upregulate specific programs and instead undergo somewhat random 
differentiation that is not tethered to the developmental signals that are present.  This effect was 
most pronounced at day 8, as was the phenotypic difference between control and knockout cells. 
However, there was a clear difference in the two cell lines as early as day 3 despite phenotypic 
similarity in flow cytometric assays. 
ChIPmentation and ATAC-seq to explore activating histone marks and chromatin accessibility 
corroborated the transcriptional profiles observed in day 8 cells. KMT2C deficient cells lacked 
H3K4me1 enhancer marks and had much more closed chromatin relative to KMT2C expressing 
cells. Thus the differences in transcription were a result of epigenetic dysregulation on a genomic 
scale. Given the magnitude of these differences it is unsurprising that there was such a severe 
phenotype in differentiation assays. It is unknown what the specific effect of this dysregulation 
would be in vivo, but it is not difficult to bridge the gap between severe transcriptional and 
epigenetic dysregulation and the development of cancer. This is especially true when the 
dysregulation is the result of a single gene, and the IL patients have additional deleterious 
variants in other genes. 
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Figure 5.1: Day 8 Sorting Schema. The populations that were sorted for downstream analysis. 
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Figure 5.2 : Volcano plot of day 8 RNA-seq data. Each transcript was plotted by fold-change 
and p-value.  The transcripts that exceeded a filter combining these two criteria were used as 
inputs for gene set enrichment analysis (red and green points) 
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Figure 5.3 : Heatmap of transcripts upregulated in day 8 KMT2C KO cells. The transcripts 
included are listed in Table 5.1 
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Figure 5.4 : Heatmap of transcripts upregulated in day 8 control cells. The transcripts 
included are listed in Table 5.2 
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Figure 5.5: Heatmap of day 8 angiogenesis genes 
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Figure 5.6: Heatmap of day 8 BMP genes 
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Figure 5.7: Heatmap of day 8 HOX genes 
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Figure 5.8: Heatmap of day 8 heart genes 
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Figure 5.9: Heatmap of day 8 hedgehog genes 
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Figure 5.10: Heatmap of day 8 MAPK genes 
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Figure 5.11: Heatmap of day 8 neuro genes 
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Figure 5.12: Heatmap of day 8 notch genes 
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Figure 5.13: Heatmap of day 8 Wnt genes 
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Figure 5.14: ChIPmentation peak heatmaps. The number of reads flanking all peaks called in 
control samples (columns 1 and 2) and KMT2C KO samples (columns 3 and 4) is depicted in the 
intensity of blue. There is a clear decrease in reads surrounding peaks in the KMT2C samples 
even in the peaks that are maintained, and a complete loss of most peaks. 
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Figure 5.15: Sorting strategy for Day 3 RNA-seq. 
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Figure 5.16: Volcano plot of d3 RNA-seq in KMT2C KO and control cells. The same plot as 
Figure 5.2, but for Day 3 RNA-seq data. 
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Figure 5.17: Heatmap of day 3 WT genes 
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Figure 5.18: Heatmap of day 3 KO genes 
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Figure 5.19: Heatmap of day 3 Axis Specification genes 
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Figure 5.20: Heatmap of day 3 Cardiovascular Development genes 
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Figure 5.21: Heatmap of day 3 Organismal Differentiation genes 
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Figure 5.22: Heatmap of day 3 Gastrulation genes 
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Figure 5.23: Heatmap of day 3 Heart genes 
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Figure 5.24: Heatmap of day 3 Neuron genes 
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Figure 5.25: Heatmap of day 3 Patterning genes 
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Figure 5.26: Heatmap of day 3 Tissue Specification genes 
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Table 5.1 Genes Significantly upregulated in Day 8 WT cells 
A2M C2orf74 CYTH3 FAM86C1 IFI27L2 MED15 OSGIN2 RAD9A SLC38A9 TLE4 ZFP3 
AACS C2orf81 D2HGDH FAM86JP IFT22 MED16 P2RY2 RARRES3 SLC39A11 TM6SF1 ZFP30 
AASDH C2orf88 DALRD3 FAM92A1 IFT52 MED22 PAAF1 RASA4B SLC44A3 TMC3 ZFP57 
ABCA11P C3 DBF4B FAXDC2 IFT74 MEF2B PABPC1 RASAL3 SLC4A3 TMC6 ZFYVE19 
ABCB10 C4A DBNL FBF1 IFT80 MEF2BNB PABPC1L RASGEF1B SLC4A8 TMEM120A ZNF101 
ABCB9 C4B_2 DBP FBXO3 IFT81 MEGF10 PAIP1 RASGRP4 SLC50A1 TMEM141 ZNF132 
ABCC4 C5orf63 DCAF11 FBXO36 IK MEIKIN PAK1 RASL12 SLC52A2 TMEM144 ZNF135 
ABCF1 C9orf64 DCN FBXO8 IKBKB METTL12 PAK3 RAVER1 SLC6A13 TMEM164 ZNF138 
ABHD16A CACNA1F DCP1B FCER1G IKZF1 METTL14 PAM RBAK SLC7A10 TMEM169 ZNF155 
ABHD2 CALCOCO2 DCTN2 FCN3 IL17RC METTL17 PAPLN RBL2 SLC7A4 TMEM170A ZNF177 
ABLIM3 CALD1 DDC FDPS IL1RAPL2 METTL23 PAPPA2 RBM22 SLC7A8 TMEM184B ZNF202 
ACAD10 CALHM2 DDHD1 FES IL3 METTL7A PARD3 RBM25 SLC9A6 TMEM209 ZNF205 
ACAN CALM2 DDHD2 FEZ1 IL32 METTL9 PARP16 RBM46 SLC9A7P1 TMEM241 ZNF207 
ACAT1 CALM3 DDI2 FGF10 IMP4 MGAT1 PAX8 RBM7 SLCO2B1 TMEM25 ZNF239 
ACBD4 CAPG DDR1 FGR INCENP MGEA5 PCDH1 RBMXL1 SLFN11 TMEM54 ZNF254 
ACKR1 CARD8 DDT FMNL3 ING1 MICAL2 PCDHA10 RCAN3 SLIT2 TMEM62 ZNF311 
ACOX1 CARS2 DDTL FOLR2 INPP4B MICB PCDHA11 RDH13 SLITRK6 TMEM92 ZNF322 
ACP6 CASP10 DDX19B FOSL2 INPP5J MKRN2 PCDHA6 REEP4 SLK TMIGD2 ZNF343 
ACPP CAST DDX54 FOXH1 IQCK MKS1 PCDHB5 RELN SLU7 TMPRSS11E ZNF346 
ACRBP CBLB DDX56 FOXI1 IQSEC2 MLF1 PCDHGB3 REXO4 SLX1B TNFRSF1B ZNF350 
ACSL6 CBLN2 DECR1 FOXJ3 IRAK1 MLH1 PCNX RFNG SMARCD2 TNFRSF9 ZNF382 
ACTC1 CBWD1 DENND2D FOXRED1 IRX6 MLST8 PCTP RGS1 SMIM11A TNFSF10 ZNF385D 
ACTR1A CBWD2 DES FPGT-TNNI3K IST1 MLX PDCD10 RGS12 SMIM11B TNFSF13 ZNF415 
ACTR2 CBWD5 DGKB FTCDNL1 ISYNA1 MME PDCD6IP RHAG SMN1 TNIK ZNF419 
ADAM15 CC2D1A DHDDS FUT8 ITGA2B MMP12 PDE1B RHBDF2 SMN2 TNIP1 ZNF429 
ADAM8 CCDC146 DHFRL1 FXN ITGAM MOK PDE6G RHBDL3 SMPD4 TNK2 ZNF454 
ADCK3 CCDC186 DHPS FXYD1 ITGB4 MPP1 PDLIM3 RHOF SMTN TNNI1 ZNF471 
ADCY7 CCDC22 DHRS4 FXYD6 ITSN2 MPZL3 PDXDC1 RHOH SMTNL2 TNNI3 ZNF506 
ADD2 CCDC68 DHRS4L1 FXYD6-FXYD2 IZUMO2 MR1 PECAM1 RIF1 SNRNP25 TNNI3K ZNF512 
ADD3 CCDC69 DHRS4L2 GABRB3 JADE2 MRAP2 PECR RILP SNRPE TNNT1 ZNF528 
ADGRE2 CCDC74B DHX30 GABRG2 JOSD1 MRPL10 PEPD RINL SNRPN TNNT2 ZNF542P 
ADGRE5 CCDC77 DHX40 GAD1 JPH4 MRPL2 PEX2 RNASE1 SORBS1 TNR ZNF544 
ADGRG6 CCDC88B DHX58 GADD45B KARS MRPL43 PEX5 RNF114 SOST TNRC6A ZNF559 
ADHFE1 CCL3L1 DIAPH3 GAL3ST1 KAT5 MRRF PF4 RNF138 SPAG16 TNS2 ZNF563 
ADORA2A CCL3L3 DISC1 GALC KAT6A MRVI1 PFKM RNF2 SPAST TNXB ZNF568 
AFAP1 CCR10 DLG1 GALNT9 KAT7 MST1R PGA3 RNF20 SPATA16 TOM1L1 ZNF570 
AGAP3 CD163L1 DLGAP4 GALT KATNA1 MTA3 PGAP2 RNF213 SPATA20 TOMM40L ZNF572 
AGBL4 CD19 DLGAP5 GANC KCNAB2 MTHFD1 PGF RNF222 SPATA7 TOX2 ZNF577 
AHCYL2 CD300A DMC1 GART KCNG3 MTHFSD PGLYRP4 RNF25 SPATS2 TP53BP1 ZNF578 
AHI1 CD300LG DMD GAS8 KCNH2 MYB PGRMC2 RNF31 SPATS2L TP73 ZNF585A 
AK4 CD33 DMGDH GATA1 KCNH6 MYBPH PHB2 RNF34 SPECC1 TPCN1 ZNF585B 
AKAP1 CD44 DMKN GATA4 KCNH7 MYCBPAP PHLDB1 RNF4 SPHK2 TPT1 ZNF589 
AKAP8L CD53 DNAAF3 GATB KCNIP2 MYL4 PHYKPL RNFT1 SPI1 TRAF3IP2 ZNF606 
AKIP1 CD6 DNAH14 GATSL3 KCNK17 MYO1F PI16 RNPEP SPIDR TRIM26 ZNF611 
AKR1C3 CD68 DNAJC4 GBA KCNMA1 MYO1G PICALM ROBO2 SPINK2 TRIM4 ZNF613 
ALAS2 CD82 DNAJC6 GBP5 KDM4C MYO3A PIGO ROBO3 SPN TRIM34 ZNF619 
ALKBH6 CDC25B DNAL4 GCA KIAA0141 MYO5A PIK3AP1 ROCK2 SPOCD1 TRIQK ZNF626 
ALMS1 CDC42EP5 DNASE1L2 GCNT1 KIAA0195 MYO5C PIK3C3 ROGDI SPOCK3 TRNAU1AP ZNF630 
ALOX5 CDH11 DOCK11 GDA KIAA1551 MYO9A PIK3R3 RPE SQRDL TROAP ZNF662 
ALPK2 CDH22 DOK3 GDAP1L1 KIF13A MYOZ1 PIK3R5 RPL10 SQSTM1 TRPC2 ZNF667 
ALS2CR11 CDH3 DONSON GDAP2 KIF23 N4BP2L1 PIN4 RPL8 SRGN TRPM3 ZNF671 
ALS2CR12 CDK11A DPM1 GFPT2 KIF5C NAA30 PIP4K2C RPP38 SRRT TRPT1 ZNF674 
AMHR2 CDK18 DQX1 GGH KIRREL2 NAALAD2 PISD RPS15 SSBP1 TSC22D3 ZNF677 
AMZ2 CDK8 DSC3 GH1 KLF1 NAALADL1 PITPNM2 RPS3A SSBP2 TSGA10IP ZNF689 
ANK3 CDKAL1 DSCAM GIN1 KLF9 NAB1 PIWIL2 RPS9 SSFA2 TSHZ2 ZNF691 
ANKRD18B CDKL4 DSCR3 GLDN KLHL33 NAGS PKP2 RPTOR SSH3 TSPAN31 ZNF726 
ANKRD24 CDKN1B DSG2 GLRA2 KRI1 NAMPT PLAU RPUSD4 SSPN TSPAN32 ZNF74 
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ANKRD40 CENPT DTD1 GLT8D1 L3MBTL4 NAP1L1 PLEK RRNAD1 SSR1 TSPAN4 ZNF778 
ANKRD53 CEP152 DUS2 GLUL LAMA2 NAP1L6 PLEKHA4 RSPO2 SSR2 TSPAN7 ZNF83 
ANKRD55 CEP350 DUSP19 GMFG LAMC2 NAPB PLEKHA6 RTEL1 SST TSPEAR ZNF880 
ANKRD6 CEP95 DYNC1LI1 GNAS LANCL1 NAT6 PLEKHF1 RUFY1 ST3GAL3 TSPYL5 ZNHIT3 
AOAH CES3 DYX1C1 GOLGA8A LARP4 NAV2 PLEKHH3 RUFY2 STAMBP TSSK6 ZNRD1 
AP1B1 CFAP44 ECHDC1 GOLGA8N LAT2 NBEAL1 PLEKHM1 RUNDC3A STARD3 TTC36 ZSCAN1 
AP1G1 CFH ECHDC3 GOSR2 LDHA NBPF26 PLSCR5 RUNX1 STAT4 TTC39A ZSCAN29 
AP1G2 CFLAR ECM1 GP6 LDLRAD4 NCAPG2 PML RUNX1T1 STAT5A TTC8 ZSCAN32 
APLP1 CFP EDC4 GPATCH4 LEF1 NDE1 PNKP RWDD4 STK11IP TYROBP ZSWIM7 
APLP2 CGN EEF1A1 GPR108 LEFTY2 NDRG1 PNP RYR1 STON2 TYW1 ZSWIM8 
APOL3 CGRRF1 EEF1B2 GPR132 LEPR NDRG2 PNPT1 S100A1 STPG1 UBA52  
ARHGAP12 CHD7 EFNA3 GPR156 LETMD1 NDUFA4L2 POLA1 S100A13 STRA6 UBE2D3  
ARHGAP26 CHKA EFR3A GPR162 LHX6 NDUFAF1 POLD2 SAMD11 STRADA UBE2F  
ARHGEF10 CHRNB1 EFTUD2 GPRC5C LIMCH1 NDUFB4 POLE2 SAMSN1 STRC UBE2I  
ARHGEF18 CIRBP EGF GPSM1 LIMK2 NDUFS7 POLR1D SAR1B STX3 UBE2L6  
ARHGEF25 CLASP2 EGFL6 GRAMD3 LIN28A NEB POLR2J3 SASH3 STXBP1 UBE2NL  
ARHGEF9 CLDN10 EGFLAM GREB1L LIN54 NEIL2 POR SASS6 STXBP2 UBE2V1  
ARRB2 CLEC10A EHD1 GRIA3 LIPT1 NEK1 POT1 SATB1 STYXL1 UHRF1BP1L 
ARSA CLEC2D EHHADH GRIP2 LITAF NELFA POTEE SCAPER SUCNR1 UMPS  
ARSG CLIC1 EHMT1 GRM4 LMF1 NEMP1 PPARA SCG5 SUGP2 UNC13D  
ART4 CLK3 EHMT2 GRN LOC100506403 NEO1 PPARG SCIN SULT4A1 UNC45A  
ART5 CLMN EIF2AK2 GSDMD LOC101928269 NFASC PPFIBP1 SCN5A SUN1 UQCRB  
ASAH1 CLPB EIF2D GSN LOC102724488 NFATC1 PPIP5K2 SCP2 SURF1 UQCRFS1  
ASB1 CLTA EIF4A1 GSR LOC102724985 NFE2 PPP1R36 SCRN1 SUV420H1 URAHP  
ASH2L CLUL1 EIF4A2 GSTM4 LOC105369230 NFKBIL1 PPP2CB SCRN2 SV2B USP39  
ASTN1 CLYBL EIF4E GSTM5 LOC105369236 NFS1 PPP2R3C SCYL1 SYNE1 VAMP1  
ATE1 CMBL ELMOD3 GSTZ1 LOC105369261 NHLRC3 PPP2R5D SDK1 SYNE2 VAMP7  
ATG16L1 CNOT2 ELP6 GTF2H2C LOC105369264 NIF3L1 PPP4R1 SEC13 SYNPO2L VAV1  
ATG3 CNOT8 EMB GTF2H2C_2 LOC155060 NIN PPP6R3 SEC14L1 SYT15 VEGFA  
ATL1 CNPY2 EML2 GUF1 LOC440311 NLGN1 PPT1 SEC31A SYT2 VEZT  
ATL2 COBLL1 EML3 GYPB LOC641367 NLN PRCC SELL SYT5 VIPR1  
ATM COG4 EMP3 GYPE LPAR5 NLRP2 PRIMPOL SELM SYVN1 VPS26B  
ATP1A2 COL1A1 ENGASE HACE1 LPCAT2 NMU PRKCB SELPLG TAB1 VPS28  
ATP2C1 COL1A2 ENO4 HADH LPL NOL8 PRKCH SEMA3E TAC3 VPS39  
ATP6V0A1 COL5A1 ENOSF1 HAND1 LRRC24 NOSIP PRKCQ SEMA4F TACR1 VRK3  
ATP8B4 COL6A1 ENPP1 HAND2 LRRC37B NOSTRIN PRKCSH SEMA5B TADA2A VWDE  
ATXN2 COL6A3 ENPP2 HAP1 LRRC61 NOTCH4 PRKCZ SEMA6C TAGLN WAC  
AXL COQ5 ENTPD1 HAPLN1 LRRC63 NPNT PRMT1 SENP2 TAOK3 WASF1  
AZI2 CORO7 ENTPD8 HAS2 LRRIQ3 NQO1 PROK1 SEPP1 TARP WBP1  
AZIN2 COX6B2 EPB41L2 HBE1 LSM12 NQO2 PRPH 4-Sep TATDN3 WDR19  
B2M CPB1 EPOR HDAC10 LST1 NR1I3 PRPSAP1 SERHL2 TAZ WDR45  
BAG6 CPED1 EPS15 HDAC11 LTBP4 NRBP2 PRR13 SERPINH1 TBC1D17 WDR74  
BAIAP3 CPNE4 EPS8L1 HDDC3 LTK NRG1 PRR14 SF3A1 TBC1D26 WDR89  
BBS2 CPNE5 EPS8L3 HDGFRP2 LUC7L2 NRXN1 PRSS57 SFRP5 TBC1D3I WDR90  
BCAS3 CPS1 ERBB2 HECTD3 LUC7L3 NRXN3 PRTG SGCA TBL1XR1 WEE1  
BCAS4 CPSF3L ERCC2 HERC5 LYPD6B NSF PRX SGSM3 TBX5 WFDC5  
BCLAF1 CRABP2 ERI1 HGF LYZ NSMAF PSMC6 SH2B1 TCAIM WLS  
BCR CREB3L4 ERLIN2 HIST1H1A M1AP NSMCE2 PSMD6 SH2D3A TCEANC WNT9B  
BEND5 CRIP1 ESPNL HIST1H3I MACROD2 NSMF PSME1 SH2D3C TCEB3 WRNIP1  
BHLHB9 CRTAC1 ESPNP HIST1H4F MADD NT5C PTAFR SH3BGR TCP10L WWP2  
BMPER CRYAB EXOC7 HIST1H4L MAGEA2 NT5C3A PTGDS SHISA5 TCP11 XIRP2  
BMPR1A CS EXOSC3 HK1 MAGEA2B NTRK1 PTGER3 SKAP1 TCTA XPNPEP1  
BNC2 CSAG3 EZH1 HKR1 MAGEA3 NUCB2 PTGIS SKIV2L TDG XPNPEP2  
BNIP2 CSF1R F2RL2 HLA-DRB1 MAGEH1 NUDT1 PTGS1 SLAIN2 TEAD4 XPO1  
BORCS8 CSF3R FAH HNRNPUL1 MAN2B2 NUP37 PTK7 SLC12A6 TECPR1 XPO6  
BROX CSTF1 FAM117A HOXA3 MAP2K5 NUP43 PTN SLC12A9 TECRL XRCC3  
BRWD1 CTF1 FAM122C HOXB2 MAP3K3 NUP93 PTP4A1 SLC13A3 TESK2 XRCC6  
BTBD9 CTGLF12P FAM131A HOXB3 MAP3K7CL NUSAP1 PTPN20 SLC15A4 TET2 XRRA1  
BTK CTNNA2 FAM156A HOXB9 MAP4K1 NXF3 PTPN6 SLC16A3 TFDP1 YAE1D1  
BTN3A3 CTNNB1 FAM156B HPS4 MAP4K4 NXN PTPRF SLC16A4 TFPI YDJC  
BTNL9 CTNNBL1 FAM20A HSCB MAPK10 OBFC1 PTPRH SLC1A5 TGFB1I1 YIPF5  
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C11orf21 CTNND2 FAM214B HSD17B4 MAPK11 OCIAD2 PTPRU SLC22A5 TGFBI YWHAE  
C11orf57 CTSB FAM222B HTATIP2 MAPK4 ODF2 PUS7L SLC25A13 TGFBR3 YWHAZ  
C12orf4 CTSF FAM227B HVCN1 MAPKAP1 ODF3B PWP1 SLC25A30 THAP7 YY1AP1  
C12orf60 CUX1 FAM234A HYAL1 MAST4 OPN3 PYCR1 SLC25A37 THAP9 ZAP70  
C16orf45 CUZD1 FAM24B HYAL3 MATN2 OPN5 PYROXD1 SLC26A10 THEMIS2 ZBED6CL  
C19orf25 CXCL10 FAM45A HYDIN MAX OPTN RAB28 SLC2A8 THOC5 ZBTB10  
C19orf57 CXCL5 FAM50A HYI MAZ OR2AG1 RAB37 SLC30A5 THRA ZBTB7C  
C1orf122 CXXC5 FAM65B IAH1 MCCC2 OR7E47P RAB3C SLC32A1 THYN1 ZCCHC10  
C1orf228 CYHR1 FAM65C IBTK MCFD2 OSBPL3 RAB43 SLC35B1 TIAM2 ZEB2  
C1QTNF4 CYP1A1 FAM72A ICA1 MDGA1 OSBPL6 RABGAP1L SLC35B2 TIPIN ZFAND1  
C1R CYP21A2 FAM72C ICAM1 MDH1 OSBPL9 RAD21 SLC35F2 TJAP1 ZFAND2B  
C2orf70 CYP4F30P FAM72D IFI16 MECOM OSCAR RAD51B SLC38A6 TLE3 ZFAND6  
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Table 5.2: Genes significantly upregulated in Day 8 KMT2C KO cells. 
A2M ATAD3A COL15A1 FLNB HPGD LAMB3 NAV3 PHC1 SCD5 SULT1E1 
ABCF1 BANP CREM FLT4 HSPA12A LGALS3 NBL1 PILRB SEL1L3 TAF1C 
ACACB BIRC7 CXCR4 FOXA1 IGFBP3 LOC100506136 NKX2-5 PLEKHG4B SELE TCF4 
AFP BTBD11 DAXX FOXA2 IGSF9 LOC101928143 NOL8 PNMA3 SEMA6B TF 
AGT C2CD4B DPEP1 G0S2 IGSF9B LOC643733 NPAS2 PRICKLE4 SERPINA1 TG 
AHSG C2orf72 DPYS GEMIN4 IHH LRWD1 NPR3 PRR26 SHFM1 TIMM22 
AMN C7orf76 DUSP4 GLDC IL17RD MAFB NPTX2 PTCHD1 SHH TSC2 
APCDD1 CDC45 DUSP9 GPC3 ISL1 MAZ NR4A1 PTPRM SLC30A1 TTR 
APOA1 CDH20 EIF1B GRB10 ITGA2 MCF2L NRD1 RAD51B SLC35F1 VIL1 
APOA4 CDK10 ELMO2 GSG1L ITGA4 MDFIC NSFL1C RBM14-RBM4 SLC39A5 VPS53 
APOB CERKL F2 HAVCR1 KIF19 MELK NUDT5 RBP4 SLC52A2 WDR47 
ARFGEF3 CHST1 FAM57A HMGCS2 KLK6 MEP1A NUMB RNF165 SON YWHAE 
ARVCF CILP2 FAM64A HNF4A KRT7 MGST3 OSBPL3 ROBO4 SOX11 ZACN 
ASGR1 CNOT8 FGB HOXD10 LAMA4 MTTP PCSK6 RPL22L1 SPTBN5 ZEB1 
ASGR2 COL13A1 FGG HOXD11 LAMB1 MYL3 PDE6B RPS20 STC1 ZNF512 
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Table 5.3 Overlapping H3K4me1 and open chromatin sites 
Sample Total ChIP Peaks Total ATAC-seq Peaks Overlapping ChIP and ATAC Peaks 
WT 16146 17362 12536 
KMT2C KO 1214 3277 153 
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Table 5.4 Significantly Upregulated Genes in Day 3 WT cells 
ACP5 CAMK2N2 DPPA4 GDF3 INPP5F MIB2 POU5F1 SHANK2 U2AF1 ZNF85 
ACTB CAMKV DPPA5 GDPD2 INPP5J MIF4GD PPAP2C SIPA1 U2AF1L5 ZNF850 
ACTRT3 CAV1 ECHDC3 GHRHR IPO13 MLKL PPP2R2B SLC25A29 UBE2D3 ZNF880 
ADAM15 CBR3 EEF1A1 GMPR2 IZUMO2 MMP25 PPP2R2C SLC25A39 UCKL1 ZNHIT3 
ADCY2 CCDC141 EFTUD2 GNAS JADE2 MNS1 PRDM14 SLC29A1 ULK4P1 ZSCAN1 
ADNP CCDC152 EML2 GPS1 JMJD1C MTHFD1 PRKAR1A SLC2A14 ULK4P2  
AFF1 CCDC47 EOMES GRHL2 JUP MUM1 PSKH2 SLC38A5 UNC13A  
AKAP1 CCM2 EPB41L4B GRID2 KCNK12 MYBPC2 PTPN14 SLC43A1 UQCC1  
ANK3 CD177 EPHA1 GRM4 KCNK17 MYH14 QRICH2 SLC45A4 UQCRFS1  
ANKLE1 CDH23 EPHX3 GSC KCTD2 MYO10 RAB17 SLC4A11 USP14  
ANKRD24 CDR2L EPS8L1 GSTM5 KIAA0930 NANOG RAB43 SLPI USP44  
AP4M1 CENPK ERBB2 GSTO1 KIFC3 NCAN RABGAP1L SMPDL3B VANGL1  
ARHGAP40 CER1 EVPL GSTO2 KIRREL2 NDE1 RAP1GAP2 SMUG1 VASH2  
ARHGDIA CERS1 EXOSC5 GYLTL1B L1TD1 NDRG4 RASSF3 SOX8 VGLL3  
ARMC8 CHGA FAM124A HAS3 LASP1 NKAPL RBFOX3 SPATA13 VRTN  
ARNTL CHRNA3 FAM155B HBA1 LGALS7 NLRP2 RBM46 SRY VSIG10  
ASCL2 CHRNB4 FAM174B HBA2 LGR5 NLRP7 RDH13 STAU1 WDR59  
ATXN7L1 CMTM3 FAM20A HBE1 LHX1 NME2 REXO2 STON2 WDR74  
B4GALNT3 CNKSR3 FAM20C HDAC3 LITAF NSG1 RFPL2 SYP WNT3  
BAG6 CNTN1 FAM24B HDAC6 LOC101929777 NSMCE4A RHBDF2 SYT3 YIPF1  
BCL11A COMT FAT3 HERPUD1 LOC102723996 OAS1 RLN2 TADA2B ZBED6CL  
BNIP3P9 COX7A1 FBLN1 HES3 LRRC45 OGFOD2 RNF2 TBC1D2 ZDHHC22  
BRINP1 CPNE7 FERMT1 HHLA1 LRRTM1 OTX2 RNF41 TDGF1 ZFP28  
BRSK2 CRABP1 FGF17 HIST1H1A LZTS1 PAIP2 RNFT2 TDP1 ZIC2  
C10orf2 CRMP1 FGFR1 HIST1H3I MAD2L2 PAQR4 RPL15 TEAD4 ZIC5  
C19orf33 CRYBB1 FOPNL HIST1H4F MAGEA2 PCBP2 RPL3L TECR ZIK1  
C1QBP CS FOXB1 HIST1H4L MAGEA2B PCDH1 RPRML TGFBR3 ZNF132  
C22orf15 CSMD1 FOXD3 HIST2H4A MAGEH1 PCDHAC1 RPS17 THEM5 ZNF217  
C2orf81 CST6 FOXK2 HIST3H2A MALL PCDHB5 RPS2P32 TJP1 ZNF253  
C2orf88 CTSF FRS2 HIST3H2BB MANEAL PCSK1N RTN4 TJP2 ZNF350  
C5orf63 CUZD1 FSHR HKR1 MAP3K9 PDCD6IP RTP1 TMEM104 ZNF385D  
C6orf136 CYP1B1 FZD5 HNRNPH1 MAP7 PDZD4 RUNX1T1 TMEM132B ZNF429  
C9orf135 DAZAP1 GABRB3 HNRNPM MAPK9 PFKFB3 SAC3D1 TNNI3 ZNF506  
C9orf64 DBNDD1 GABRQ HPCAL1 MARVELD3 PIKFYVE SCGB3A2 TRIM27 ZNF528  
CA2 DKC1 GALK2 HPDL MATK PIWIL2 SEC14L1 TRIML2 ZNF585A  
CACNA1B DKK4 GAS8 HSPA8 MDGA2 PLEC SELENBP1 TRNP1 ZNF585B  
CACNG5 DMRTB1 GATA6 ICOSLG MECR PLEKHF1 SELT TRPM2 ZNF667  
CALB1 DNAJC14 GATAD2B IDO1 MEN1 PLEKHG6 SENP2 TSACC ZNF677  
CALB2 DND1 GCFC2 IGFBP2 MESP2 POC1B SEPHS1 TTC9 ZNF74  
CALCR DNMT3B GDF1 IGFLR1 MGAT4C POU2AF1 SFRP2 TTN ZNF829  
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Table 5.5 Significantly Upregulated Genes in Day 3 KMT2C KO cells 
ABR CCM2 DGKH FOXD1 HN1L LPIN1 NECAB2 PEMT SATB2 TM9SF4 
ACTA2 CD59 DHRS3 FOXQ1 HOXA4 LRRC4C NELL2 PGM3 SCD5 TNFRSF19 
ADD1 CDH11 DIS3L2 FOXS1 HOXB6 LTBP4 NKX2-5 PHC2 SDC2 TPCN1 
ALDH1A2 CDK11A DNM2 FREM2 HPS1 MAP3K13 NOL3 PIN1 SELENBP1 TPPP 
ALX1 CENPBD1P1 DOK6 FSD1 ID1 MAPK15 NPR3 POMT2 SEMA3D TRAF4 
ANGPTL4 CERS3 DUSP15 FTH1 IHH MCCC2 NRBP2 PPP1R32 SEPT11 TSPAN4 
APOA1 CHAD DUX4L50 G0S2 ILK MCOLN3 NRGN PPP2R4 SEPT3 ULBP1 
APOPT1 CHD3 EGFLAM GEMIN4 IP6K2 MDK NRP1 PPP2R5C SHISA5 UNC5C 
ARL4C CIRBP EHMT2 GLMN KANSL1 MED15 NSUN6 PRICKLE1 SHMT2 URAD 
ASB1 CLK1 EIF4E3 GLOD4 KAZALD1 MED24 NTRK2 PRRC2A SLC35B1 USP14 
BFAR COTL1 EPB41L3 GNAI2 KCNQ2 MEIS2 NTRK3 PRTG SNRPN VDAC2 
BMI1 CPA2 EPHB4 GOLGA8A KCP METTL3 NUDT1 PTCHD4 SPATA7 VEGFA 
BRWD1 CPXM1 EXOC5 GPSM1 KDM2A MFGE8 NUP107 RABL2A SPPL3 VPS53 
C10orf11 CRB2 EXOSC9 GREB1L KRT16 MLLT3 NUP58 RABL2B STRA6 VSIG2 
CAD CSF1 FAM120AOS GSN KRT16P3 MMP16 NXN RAD51 TBL1X WDR6 
CARD8 CST3 FAM134A HAND2 LARP7 MMP28 PAPPA RBM20 TCF25 YWHAE 
CBWD2 CYB5A FAM57A HDAC11 LCN15 MNX1 PCED1A RGPD5 TCF3 ZBTB16 
CBWD5 CYP27A1 FAM84A HDHD2 LEF1 MOV10 PCGF1 RGPD6 THY1 ZDBF2 
CBWD6 DCDC2 FBLIM1 HES7 LINGO1 MTRNR2L4 PCSK5 RNMTL1 TIMM22 ZNF503 
CCDC144NL DCTN2 FNTA HHIPL2 LIPG NBPF15 PDPR RPL9 TLX1 ZNF681 
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6. Discussion 
6.1 Progress in Cancer Research and Infant Leukemia 
Over the last several decades, dedicated researchers have vastly increased our understanding of 
the constellation of diseases known as cancer8,163,164. We better understand the genetic basis of 
many cancers, the specific driver mutations present and the clonal heterogeneity present in 
tumors17,165–167. We have developed promising new therapies and treatments168–170. However, 
over that same period, therapy and outcomes for IL have remained largely unchanged136,171. 
Many different treatment protocols for IL have been tested26–28, but none has been able to 
improve outcomes in an appreciable way. Similarly, the same approach to tumor-normal 
sequencing that have provided a wealth of information in adult cancers17,18,131,172, has failed to 
meaningfully inform IL22. The failure of standard approaches to achieve meaningful progress 
suggests that, instead of viewing IL as a disease very much like adult leukemia, but occurring in 
an infant, we should view the disease as a separate entity with unique genetic features and 
developmental origins. Indeed, a new paradigm for understanding IL needs to be developed. 
6.2 The Genetic Basis of IL 
In this work, we provide some explanation as to why IL is distinct from many other cancers. 
Somatic variation is much less present in IL than in other cancers. We hypothesized that 
leukemia-predisposing germline variants might make up the majority of the “drivers” required 
for leukemogenesis. There were hints that this might be the case for years. Cases of concordant 
leukemia in identical twins were well known. They supported the notion that the genetic 
environment might play a role in the development or maintenance of leukemic cells. Further 
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evidence for a germline genetic basis for leukemia is seen in the increased risk of ALL between 
fraternal twins and non-twin siblings173. The evidence that childhood cancer, and IL in particular 
might be more like an inherited complex trait and not a somatic disease was there, but not 
conclusive. In this work, we provide the strongest evidence to date that germline variation is an 
important factor in IL and that it might contribute more to disease than do somatic events. 
6.3 The Developmental Context of IL 
IL develops before birth. Many signaling pathways, cell types and processes are seen exclusively 
during in utero development. These developmental processes lay the foundation for the huge 
variety of adult tissues and organs, so small perturbations early on might have serious 
consequences later on. Both of these facts should be considered in IL. Our hPSC modeling is 
consistent with the leukemic transformation occurring in cells derived from the primitive 
hematopoietic program. This is almost certainly not the case in adult leukemias. Even if the cell-
of-origin in IL is not primitively derived, the early onset of disease suggests that the 
transformation likely occurs in a more immature cell-type than leukemias occurring later in life. 
If this is the case, then they would be expected to have distinct behaviors and responsiveness to 
treatment relative to their definitively derived counterparts. This possibility is much more likely 
given the burden of deleterious germline variation present in IL patients.  If the disease required 
somatic mutation to occur, then several of these rare events would have to occur very early on, in 
the same cell and in cancer causing genes or positions.  This is incredibly unlikely.  However, if 
the majority of the variation required to develop IL is present in every cell from the time of 
conception, then the likelihood of receiving the final insult in the transient, immature cells seen 
only during development is much higher. This idea remains speculative, as we have not 
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transformed cells in vitro, but it is compelling to think that many of the differences between IL 
and leukemias later in life was a result of the cell-off-origin.  This is further supported by the two 
studies in which the leukemia that was generated through in vitro hematopoietic differentiation 
was likely primitively derived151,152. Further studies on this point are needed. 
6.4 Conclusions 
This study provides insights into the biology of IL. It supports the hypothesis that germline 
variation, rather than somatic events, are the relevant genetic events in this disease. It shows that 
genes found to have significant deleterious variation in IL patients exert, in at least one case, a 
strong influence on the developing hematopoietic system. Using this system, it also shows that 
the developmental origins of IL might be different from any other cancer. While these findings 
are novel and raise many interesting questions, this is an admittedly modest contribution to IL 
specifically and the larger world of cancer biology generally. It will be fascinating and rewarding 
to see how this work inspires future research, and this progress will build on and clarify 
observations made here. 
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